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Abstract
Critical lower limb ischaemia (CLI) is the most severe form 
of peripheral arterial disease (PAD). Even though the treatment of 
CLI has evolved during the last decade, CLI is still associated with 
considerable morbidity, mortality and decreased quality of life, in 
addition to a large financial impact on society. Infrainguinal bypass 
surgery has traditionally been considered the approach of choice 
for treating CLI patients in order to avoid amputation. However, 
there are increasing data on the efficacy of 
endovascular revascularization procedures 
to achieve good leg salvage rates as well. 
The main aim of the present study was to 
compare percutaneous transluminal angio-
plasty (PTA) and bypass surgery in the treat-
ment of CLI. Additionally, predictors of the 
failure of PTA for CLI were sought, the re-
producibility of the TASC II classification of 
femoropopliteal arterial lesions was tested 
and communication between vascular sur-
geons and interventional radiologists was 
evaluated.  
Data gathered on all the 2,054 CLI pa-
tients revascularized at the Helsinki Uni-
versity Central Hospital between 2000 and 
2007 were analyzed retrospectively. This 
patient cohort was used to compare the re-
sults of PTA and bypass surgery as well as 
to investigate predictors of failure after PTA. 
Propensity scores can be used for identify-
ing patients with similar chances of receiv-
ing one treatment or the other, thus permit-
ting non-randomized comparisons of treat-
ment outcomes. Consequently, the propen-
sity score analysis was used for regression 
adjustment and for one-to-one matching in 
the studies comparing PTA and surgical re-
vascularization. To test the TASC II classi-
fication, 200 angiographies were evaluated 
by seven investigators, comprising vascular 
surgeons and radiologists. Finally, 351 conse-
quent referrals made by vascular surgeons 
to radiologists for digital subtraction angi-
ography (DSA) with or without a request for 
an intervention at the Helsinki University 
Central Hospital during 2007 were scruti-
nized. These and the procedures performed 
accordingly at the Department of Radiology 
were evaluated.  
When the treatment method was adjusted 
for propensity score as well as in the propen-
sity-score-matched pairs, infrainguinal PTA 
and bypass surgery yielded similar results at 
5 years in terms of survival, amputation-free 
survival (AFS) and freedom from any re-in-
terventions. However, when the femoropo-
liteal segment was treated, leg salvage was 
significantly better in the surgical revascu-
larization group at 5 years, whereas no sig-
nificant difference was observed between 
the two treatment methods when the revas-
cularization extended to the infrapopliteal 
segment. Infrainguinally, PTA resulted in 
significantly lower freedom from surgical 
re-interventions when compared to surgi-
cal revascularization. 
The patient’s nonambulatory status upon 
hospital arrival was a significant predictor 
of death, amputation and surgical re-inter-
vention after PTA. Gangrene was a signifi-
cant predictor of amputation and was more 
strongly associated with it than the presence 
of an ulcer. 
The inter-observer agreement on the TASC 
II classification of femoropopliteal lesions 
proved to be inadequate.
The informational content of the refer-
rals made by vascular surgeons frequent-
ly proved to be inadequate. The radiologists 
made treatment alterations at their own dis-
cretion in 20% of the instances, and these 
resulted in significantly more complications 
and/or technical failures than when the re-
ferral request was followed or a vascular sur-
geon was consulted beforehand. 
In conclusion, when technically feasible, 
infrainguinal PTA seems to be a valid alter-
native for bypass surgery in the treatment of 
CLI when redo-surgery is actively utilized. 
However, at the femoropopliteal level, PTA 
might be associated with poorer leg salvage 
in the long term when compared to bypass 
surgery, although the treatment method did 
not affect AFS. Bypass surgery could likely 
be considered as a better alternative in pa-
tients with probable longevity.
Strong predictors of poor outcome after 
PTA for CLI are nonambulatory status up-
on hospital arrival and gangrene as a man-
ifestation of CLI. 
The TASC II classification of femoropoplite-
al arterial lesions allows individual interpre-
tations, and its reproducibility seems to be 
rather poor. Its common use as a basis for 
therapeutic decision-making and reporting 
outcomes in scientific literature can there-
fore be questioned.
The communication between vascular sur-
geons and interventional radiologists seems 
to be insufficient to ensure optimal treat-
ment for CLI patients. A mixed team ap-
proach could help decrease these prob-
lems. ❦
14
Chronic critical limb ischaemia 
Introduction
Critical limb ischaemia (CLI) is the most severe form of peripheral 
arterial disease (PAD). In CLI there is lack of sufficient arterial blood 
flow to accommodate the metabolic requirements of the resting tis-
sues, thus threatening the viability of the distal extremities. This is 
usually caused by multilevel arterial occlusive disease, frequent-
ly involving the infrainguinal vessels (Veith et al. 1990). As the pop-
ulation is aging and the amount of diabetic patients growing, CLI 
presents an expanding challenge for the health care system (Hirsch 
et al. 2008, Shaw et al. 2010). Even though advances in the treatment 
of CLI have been made during the last decade, the prognosis of CLI 
patients remains poor. CLI is associated with considerable morbidity, mortality and a de-
creased quality of life, in addition to a large financial impact on so-
ciety (Norgren et al. 2007).    
Definition of CLI
CLI is defined as ischaemic rest pain persisting at a level requir-
ing analgesics for at least 2 weeks or non-healing pedal ulcers or 
gangrene attributable to objectively proved arterial occlusive dis-
ease (Dormandy et al. 2000, Norgren et al. 2007, Second European Con-
sensus Document 1991). In the North American recommendations 
for reporting standards (Rutherford et al. 1997), CLI is equivalent 
to the grades II and III which include the categories 4, 5 and 6 (Ta-
ble 1). Accordingly, in the classification of chronic limb ischaemia 
according to Fontaine (Fontaine et al. 1955), stages III and IV rep-
resent CLI (Table 2). 
There are varying recommendations regarding the level of objec-
tive circulatory impairment that is required to qualify for CLI (Sec-
ond European Consensus Document 1991, Rutherford et al. 1997). De-
Introduction and  
review of the literature
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pending on symptoms (rest pain or tissue 
loss), the Trans Atlantic Inter-Society Con-
sensus (TASC) II suggests the use of ab-
solute pressures of either ankle pressure 
(AP) less than 50–70 mmHg, toe pressure 
(TP) less than 30–50 mmHg or transcuta-
neous partial pressure of oxygen (tcPO2) 
at the foot of less than 30–50 mmHg as 
the definition criterion for CLI (Norgren et 
al. 2007). 
Incidence and natural history of CLI 
The incidence of CLI is not known with cer-
tainty. However, indirect evidence has been 
gathered from studies examining the pro-
gression of intermittent claudication (IC), 
population surveys on prevalence as well as 
assumptions based on major amputations, 
and the thereby estimated incidence of CLI 
among the European population is 400–
652 per 1 million every year (Catalano 1993, 
Critical limb ischaemia: management and out-
come 1995). As the population is ageing and 
the number of diabetics growing, the inci-
dence of CLI is estimated to increase signif-
icantly in the future (Allie et al. 2009, Shaw 
et al. 2010).
The antecedent natural history of CLI is 
not well understood. It is appealing to as-
sume that patients progress through the 
Fontaine stages in a stepwise manner – 
however, evidence from several studies 
suggests otherwise. For instance, a multi-
center prospective study evaluating 713 pa-
Table 1.
Clinical categories of chronic limb ischaemia according to Rutherford 
(Modified froM rutherford et al. 1997)
Grade Category Clinical description Objective criteria
0  0
Asymptomatic — no haemodyna-
mically significant occlusive disease
Normal treadmill or reactive  
hyperaemia test
1 Mild claudication
Completes treadmill exercise; AP  
after exercise >50 mm Hg but at least 
20 mm Hg lower than resting value
I 2 Moderate claudication Between categories 1 and 3
3 Severe claudication
Cannot complete standard  
treadmill exercise and AP after  
exercise <50 mm Hg
II 4 Ischaemic rest pain
Resting AP <40 mm Hg,  
flat or barely pulsatile ankle or  
metatarsal PVR; TP <30 mm Hg
III 5
Minor tissue loss — nonhealing  
ulcer, focal gangrene with diffuse 
pedal ischaemia
Resting AP <60 mm Hg,  
ankle or metatarsal PVR flat or barely 
pulsatile; TP <40 mm Hg
6
Major tissue loss — extending above 
TM level, functional foot no longer 
salvageable
Same as category 5
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tients requiring amputation for ischaemic 
disease showed that more than half the pa-
tients did not have any symptoms of leg 
ischaemia whatsoever in the preceding 6 
months (Dormandy et al. 1994). Although this 
study was not limited to CLI patients on-
ly, other studies have shown similar results 
(Mätzke and Lepäntalo 2001, Nehler et al. 2003). 
One possible explanation for this could be 
the co-morbidities of the CLI patients mak-
ing them less likely to ambulate to an ex-
tent that would promote symptoms of clau-
dication. In any case, these studies imply 
that the progression of PAD to CLI is un-
predictable. 
As the majority of patients presenting 
with CLI today receive some form of ac-
tive treatment, it is no longer possible to 
describe the natural history of the disease. 
Those CLI patients who are unsuitable for 
reconstructive arterial surgery are not rep-
resentative of the whole CLI patient popu-
lation (Lepäntalo and Mätzke 1996), and using 
their outcome as an indicator of the natural 
history of CLI is therefore skewed.
Fate of the patient with CLI
The severity of the systematic atherosclero-
sis is accurately reflected by the severity of 
PAD. The prognosis for patients with CLI 
is indeed poor due to the diffuse multilevel 
nature of the arterial obstruction and con-
current cardiac and cerebrovascular co-mor-
bidities (Hirsch et al. 2006). Patients with se-
vere PAD may have an up to 15-fold great-
er overall risk of cardiovascular mortality 
than those without the disease (Criqui et al. 
1992). Approximately 80% of CLI patients 
will die from a vascular event, with the lead-
ing cause of death being myocardial infarc-
tion (MI) (Jämsén et al. 2002, Regensteiner et 
al. 2002, Walker et al. 1998). In a Finnish pro-
spective study, the survival rate of 100 CLI 
patients treated with percutaneous translu-
minal angioplasty (PTA) was compared with 
that of the sex- and age-matched control 
population living in the same area, reveal-
ing a remarkable difference in favour of the 
control group (Jämsén et al. 2002). The fate of 
the patient and the limb seems to depend on 
the severity of CLI. Within 10 years, the mor-
tality of patients presenting with ischaemic 
rest pain can reach 80%–85% and of those 
with gangrene 95% (Dormandy et al. 1999b, 
Walker et al. 1998). In a review by Wolfe and 
Wyatt, 20 recent publications reporting the 
results of 6,118 patients with CLI were eval-
uated; the risk for limb loss at 1 year was 
estimated to be 70% for patients with rest 
pain and 95% for patients with tissue loss, 
if they were treated conservatively (Wolfe and 
Wyatt 1997). 
Revascularization can significantly reduce 
the need for amputation for CLI patients (Es-
kelinen et al. 2005, Kudo et al. 2006, Luther 
et al. 2000, Wolfe and Wyatt 1997). There are 
worldwide estimations that the primary am-
putation rate for CLI patients is 25%, and 
approximately 50% of patients with CLI 
will undergo some type of revascularization 
(Norgren et al. 2007). Furthermore, one year 
thereafter roughly 25% of the patients will 
have died, some 30% will be alive with their 
leg amputated and approximately 20% will 




IIB Moderate to severe claudication
III Rest pain
IV Ulceration or gangrene
Table 2.
Clinical classification of chronic  
limb ischaemia according to Fontaine  
(Modified froM NorgreN et al. 2007)
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Risk factors for CLI
Risk factors for developing CLI are similar 
to those of PAD (Table 3). Of these, the fac-
tors most strongly associated with the pro-
gression of PAD to CLI seem to be diabetes 
mellitus, cigarette smoking and age. These 
risk factors seem to be independent, and 
therefore the risk for developing CLI ap-
pears to be the sum of their effect (Norgren 
et al. 2007; Figure 2). 
The ankle-brachial index (ABI) is an indi-
cator of generalized atherosclerosis, for low-
er levels have been associated with higher 
rates of concomitant coronary artery disease 
(CAD) and cerebrovascular disease (CVD) 
as well as with the presence of cardiovascu-
lar risk factors (Newman et al. 1993). ABI de-
creases as the functional severity of PAD in-
creases, and the lowest ABI values are mea-
sured in legs with gangrene (Zierler et al. 
2005). Consequently, decreasing ABI is asso-
ciated with the risk of developing CLI (Nor-
gren et al. 2007). 
Diabetes
Diabetes is a strong risk factor for PAD, and 
diabetic patients are four times more likely 
to develop CLI than non-diabetic patients 
(Norgren et al. 2007). Almost half of the pa-
tients with CLI have diabetes; in a retrospec-
tive survey based on the Finnish national 
vascular registry (Finnvasc) including 5,709 
operations for CLI, 44% of the patients were 
diabetics (Virkkunen et al. 2004), with other 
studies revealing similar numbers (Dick et 
al. 2007). Yet, the number of diabetic pa-
tients is increasing dramatically, and it is 
estimated that diabetes affects 6.4% of the 
world’s population and that the amount of 
diabetics will increase to 7.7%, thus affect-
ing as many as 439 million adults by the 
year 2030 (Shaw et al. 2010).
The peripheral neuropathy associat-
ed with diabetes can mask ischaemic rest 
pain, leading to delayed diagnosis of CLI; di-
abetics have tissue loss as an indication for 
treatment for CLI more often than non-dia-
betics (Virkkunen et al. 2004). Approximate-20
Figure 1
Fate of the patients presenting with CLI
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ly 50% of diabetic foot ulcers are of neu-
roischaemic/ischaemic aetiology (Gershater 
et al. 2008, Prompers et al. 2007). The risk of 
developing gangrene is 20 to 30 times high-
er in diabetics with PAD when compared 
with non-diabetics with PAD (Dormandy et 
al. 1999a). Diabetics are 5 to 10 times more 
likely to require an amputation than are 
non-diabetic patients (Dormandy et al. 1999a, 
Jude et al. 2001). 
Diabetes predisposes to an infragenicular 
atherosclerotic disease which may spread at 
an accelerated rate and lead to faster pro-
gression of intimal hyperplasia at anasto-
moses or angioplasty sites (Dick et al. 2007, 
Diehm et al. 2006). The consequences of this 
are earlier and higher rates of re-stenosis af-
ter invasive treatment (Dick et al. 2007). 
 
Smoking
Cigarette smoking is a powerful aetiolog-
ic risk factor for PAD and is also strongly 
associated with the risk of developing CLI 
(Criqui et al. 1997, Norgren et al. 2007). The 
amount and duration of cigarette smoking 
correlate directly with the development and 
progression of PAD – heavy smokers have a 
four-fold higher risk of developing IC com-
pared with non-smokers, and the diagnosis 
of PAD is made approximately a decade ear-
lier in smokers than in non-smokers (Dor-
mandy et al. 1999, Freund et al. 1993, Norgren 
et al. 2007). A positive association between 
passive smoking and the prevalence PAD 
has additionally been demonstrated in a 
population-based cross-sectional survey of 
1,209 Chinese female never-smokers (He et 
al. 2008). 
Dyslipidaemia
The lipid risk profile is similar between pa-
tients with PAD and those with CLI (Dorman-
dy et al. 2000). Elevated total and low-densi-
ty lipoprotein (LDL) cholesterol and lowered 
high-density lipoprotein (HDL) cholesterol 
levels, as well as hypertriglyceridaemia are 
associated with PAD (Fowkes et al. 1992, Mu-
rabito et al. 2002, Newman et al. 1993). Yet, the 
evidence of dyslipidaemia as an indepen-
dent risk factor for CLI is scarce and mostly 
extrapolated from studies on CAD. 
Age
The incidence and prevalence of PAD in-
crease sharply with advancing age (Bainton 
et al.1994, Meijer et al. 1998), and age is also 
associated with the progression of PAD to 
CLI (Dormandy et al. 1999a).
Diagnosis of CLI
Clinical presentation and physical examination
One of the cardinal symptoms in CLI is 
limb pain at rest, which presents as a burn-
ing dysesthaesia of the foot and is typical-
Table 3
Risk factors for peripheral arterial disease (Modified froM NorgreN et al. 2007)
Cigarette smoking Hyperhomocysteinaemia
Diabetes mellitus  Chronic renal insufficiency
Hypertension Hyperviscosity and hypercoagulable states
Dyslipidaemia Race (Asian/hispanic/black vs. white)
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ly aggravated by elevation and relieved with 
dependency (Nehler and Wolford 2005). It 
may be accompanied by pain caused by 
peripheral ischaemic neuropathy. Typical-
ly, narcotic analgetics are required to treat 
the pain. In diabetics this symptom of CLI 
may be masked by concomitant neuropa-
thy, which impairs sensory feedback (Nor-
gren et al. 2007).
CLI may also present as an ischaemic 
skin lesion, that is, ulcer or gangrene. 
Some ulcers may be purely ischaemic in 
nature, whereas others may have other ini-
tial aetiologies such as trauma, venous in-
sufficiency or neuropathy, but they fail to 
heal due to underlying PAD. An ischaemic 
ulcer is typically located in the tip of a toe 
or between toes, but may occur anywhere 
below mid-calf (Burkitt et al. 1998, Hirsch 
et al. 2006). Additionally, an ischaemic ul-
cer characteristically has irregular margins 
and is dry, pale or pink-based and is pain-
ful in the absence of sensory neuropathy 
(Hirsch et al. 2006, Norgren et al. 2007). Gan-
grene typically affects the toes, but pres-
sure points, such as the heel, may also be 
affected. When severe, gangrene may in-
volve the distal parts of the forefoot (Nor-
gren et al. 2007). 
It is important to determine the time 
course of development of ischaemic symp-
toms, for CLI is rather a disease process that 
occurs in the chronic setting of months to 
years and is not to be confused with acute 
occlusion of the distal arterial tree. The vas-
cular history should also include the as-
sessment of arterial disease in other terri-
tories (especially CAD and CVD) and glob-
al risk factors for atherosclerosis (Hirsch et 
al. 2006). By pulse palpation it may be pos-
sible to roughly estimate the level of signifi-
cant arterial obstruction. If the pulse of both 
the dorsalis pedis and tibial posterior arter-
ies is palpable, the possibility of a signifi-
cant arterial disease is unlikely (Lepäntalo et 
al. 2000). Yet, the interpretation of pulse pal-
pation may be more uncertain than general-
ly believed (Lundin et al. 1999). The diagnosis 
of CLI should be confirmed with objective 
noninvasive testing; primarily by ABI and, 
when necessary, also by TP or tcPO2 mea-
surement (Norgren et al. 2007).22














The approximate magnitude of the effect of risk factors on the development of CLI in patients with PAD 
(Modified froM NorgreN et al. 2007)
Pressure measurements
Ankle pressure and the ankle-brachial index
The functional severity of PAD can be eval-
uated by measuring the ankle systolic blood 
pressure, which has become a standard part 
of the initial evaluation of patients with sus-
pected PAD (Norgren et al. 2007, Zierler et 
al. 2005). It is measured by placing a pneu-
matic cuff around the ankle just above the 
malleolus level, and the systolic blood pres-
sure from both the dorsalis pedis and pos-
terior tibial arteries is then recorded with 
a Doppler probe. However, the ankle pres-
sure varies with the central aortic pressure 
and it is therefore convenient to normalize 
these values by dividing the ankle pressure 
by the brachial blood pressure. This ratio is 
referred to as ABI (Zierler et al. 2005).
ABI ≤ 0.9 is considered indicative of the 
presence of PAD. The ABI values are con-
sidered mildly to moderately diminished 
when they are between 0.41 and 0.9 and se-
verely decreased when ≤ 0.4 (Hirsch et al. 
2006). With lowering ABI, the haemody-
namic severity of the occlusive disease be-
comes greater (Norgren et al. 2007).   
ABI may be inaccurate if the tibial ves-
sels at the ankle become non-compress-
ible, as may occur in patients with diabetes. 
Falsely elevated ABI may also be encoun-
tered in patients with renal failure or in very 
elderly individuals. These patients typical-
ly have an ABI >1.4. Despite the artificial-
ly elevated ABI, these patients may suffer 
from significant PAD. Therefore, addition-
al non-invasive diagnostic testing (e.g., TP 
or pulse volume recording), should be per-
formed for these patients if they have symp-
toms strongly suggestive of PAD (Hirsch et 
al. 2006, Norgren et al. 2007).
The ABI provides prognostic information 
about the patient’s survival; ABI values < 0.9 
and >1.4 were demonstrated to be associat-
ed with increased all-cause and cardiovascu-
lar mortality in a retrospective cohort study, 
The Strong Heart Study (SHS) by Resnick et 
al., including 4,393 American Indians (Resn-
ick et al 2004a). These results have been fur-
ther supported by later studies (Ankle Bra-
chial Index Collaboration 2008, Suominen et 
al. 2010). An analogous, U-shaped associa-
tion seems to exist between ABI values and 
major amputation rates as well. In a retro-
spective, registry-based study by Marston 
et al., evaluating 142 conservatively treated 
patients presenting with an ischaemic ul-
ceration, ABI <0.5 seemed to be associated 
with an elevated risk of limb loss (Marston et 
al. 2006). On the other hand, falsely elevat-
ed ABI (>1.4) was associated with a signifi-
cant increase in the risk for leg amputation 
in a subgroup analysis of the SHS, which 
included 1,974 diabetic American Indians, 
and a similar association was also shown 
in a registry-based study by Silvestro et al., 
evaluating 299 patients with 325 critically 
ischaemic limbs (Resnick et al. 2004b, Silves-
tro et al. 2006).
Toe pressure and the toe-brachial index
AP measurements fail to reflect the severi-
ty of peripheral ischaemia when there is ex-
tensive pedal or digital arterial disease or 
when the leg arteries have become non-
compressible due to medial calcification. 
This problem may be obviated by measur-
ing pressures at toe level where the vessels 
are seldom affected by calcification (Ramsey 
et al. 1983).
TP is measured with a pneumatic cuff 
wrapped around the proximal phalanx of 
the first or second toe with a flow sensor ap-
plied distally. TP is normally approximately 
30 mmHg less than the AP. The toe-brachi-
al index (TBI) is yielded by dividing the toe 
pressure with brachial pressure. TBI < 0.7 is 
considered diagnostic of PAD (Hirsch et al. 
2006, Norgren et al. 2007, Zierler et al. 2005). 
Imaging techniques
The anatomic pattern of the disease is an 
important factor when considering the type 23
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of procedure for revascularization. Suffi-
cient inflow and outflow have to be con-
firmed before taking up invasive measures. 
Diagnostic accuracy is an important factor 
when choosing the imaging modality – how-
ever, potential adverse effects, contraindica-
tions, cost, local availability and experience 
should also be taken into account.
Heretofore digital subtraction angiography 
(DSA) has been the standard of reference in 
the evaluation of lower extremity arterial dis-
ease. It is an invasive procedure with sub-
stantial costs and a risk, although small, of 
complications (Waugh et al. 1992). Non-inva-
sive or minimally invasive techniques for an-
atomic assessment of the peripheral arteries 
that could replace DSA would therefore be 
desirable. Indeed, in recent years, non-inva-
sive and thus potentially safer and more con-
venient imaging techniques have developed 
rapidly. As has happened already in many 
vascular units, the trend seems to be that the 
non-invasive modalities will largely replace 
DSA as the primary tool for planning and fol-
low-up of revascularization, thus reserving 
DSA for targeted therapeutic use (Insko et al. 
2005, Lakshiminarayan et al. 2009).
Digital subtraction angiography 
DSA is regarded as the gold standard for in-
terventional planning. It provides excellent 
resolution, and endovascular interventions 
can be performed in conjunction with it 
(Ayerdi et al. 2005). However, DSA has several 
liabilities. It involves radiation exposure and 
risks of complication associated with the ar-
terial puncture and catheter manipulation – 
i.e., bleeding from the puncture site, intra-
arterial thrombosis and vessel perforation. 
DSA carries an approximately 0.7% risk of 
a complication that is severe enough to al-
ter patient management and a 0.16% mor-
tality risk (Norgren et al. 2007).
The use of an iodinated contrast medium 
includes a risk of a severe contrast reaction 
of about 0.1%. Iodinated contrast agents are 
also associated with potential nephrotoxic-
ity, and patients at increased risk of con-
trast nephropathy are those with baseline 
renal dysfunction, low cardiac output, dehy-
dration or diabetes (Hirsch et al. 2006, Nor-
gren et al. 2007). For patients at risk, vigor-
ous hydration before contrast administra-
tion may prevent the deterioration of renal 
function (Hirsch et al. 2006). The occurrence 
of nephrotoxicity appears to be dose-depen-
dent, and therefore the amount of contrast 
medium used should be kept at minimum 
(Hirsch et al. 2006).
If iodinated contrast medium is contra-
indicated, it is possible to use either car-
bon dioxide (CO2) or gadolinium to opacify 
the arteries for angiography. However, with 
the use of CO2 the image quality is infe-
rior to that obtained with the use of an io-
dinated contrast medium (Ayerdi et al. 2005). 
Nephrotoxicity is also a potential issue with 
gadolinium, as it has been shown to cause 
acute renal failure in patients with underly-
ing chronic renal insufficiency on rare occa-
sions (Sam et al. 2003). Gadolinium adminis-
tration for patients with renal dysfunction 
has also been associated with a rare, but se-
vere and potentially lethal condition, name-
ly nephrogenic systemic fibrosis (NSF) (Pen-
field et al. 2007).
Colour-assisted duplex ultrasonography 
In expert hands, colour-assisted duplex ul-
trasonography (DD) can provide most of 
the essential information of the anatom-
ic location and degree of the arterial steno-
sis, but the crural arteries are challenging 
to image in their entirety (Hirsch et al. 2006, 
Norgren et al. 2007). DD is completely safe 
and a widely accessible method for vascular 
imaging, and the cost is rather low as com-
pared to other modalities. DD is highly de-
pendent on technical skill and thus suscep-
tible to inter-observer variation (Norgren et 
al. 2007, Ubbink et al. 2001). The accuracy of 
DD may be diminished, for example, due 24
to calcifications, obesity or oedematous soft 
tissues that obscure the visibility of the ar-
teries (Eiberg et al. 2010).
Irrespective of the degree of ischaemia, 
the agreement between DSA and DD seems 
to be rather good in the femoropopliteal ar-
teries, but is poorer in the infrapopliteal ar-
eas (Favaretto et al. 2007, Eiberg et al. 2010). 
The specificity of DD for detecting signifi-
cant stenoses or occlusions seems high, al-
though its sensitivity seems to be lower and 
also inferior to both magnetic resonance an-
giography (MRA) and computed tomogra-
phy angiography (CTA) (Collins et al. 2007, 
Favaretto et al. 2007, Löfberg et al. 2001, Visser 
and Hunink 2000). Despite this, a prospec-
tive controlled study on 114 patients by Ko-
elemay et al. showed that in a vascular unit 
with wide expertise in DD, the management 
of patients with severe leg ischaemia could 
be based on DD in most patients without 
negative effects on clinical outcome, when 
compared to the control group within 30 
days and at 2 years’ follow-up (Koelemay et 
al. 2001b).
Magnetic resonance angiography 
In many centres, three-dimensional gadolin-
ium-enhanced (3D-Gd) MRA is the preferred 
method for imaging the peripheral vascula-
ture (Lakshminarayan et al. 2009, Norgren et 
al. 2007). MRA has become an accepted stan-
dard of evaluation for PAD, for it is minimal-
ly invasive and has been demonstrated to be 
highly accurate (Collins et al. 2007, Koelemay et 
al. 2001a, Steffens et al. 2003). A systematic re-
view by Collins et al. including 58 studies on 
diagnostic accuracy and a meta-analysis by 
Visser and Hunink suggests that the sensitiv-
ity of MRA to detect PAD is superior to DD 
(Collins et al. 2007, Visser and Hunink 2000). A 
prospective study by Langer et al. compared 
MRA and DSA in a series of 29 CLI patients 
and indicated that MRA may be better at de-
tecting pedal bypass target arteries (Langer et 
al. 2009). An additional advantage of MRA 
lies in its 3D properties that may allow su-
perior spatial depiction of eccentric or com-
plex stenoses (Lakshminarayan et al. 2009, Nor-
gren et al. 2007).
Early venous enhancement due to fast ar-
terial flow and venous shunting may be a 
problem when imaging infrapopliteal vessels 
with MRA in patients with CLI, cellulitis, ul-
ceration or diabetes (Foo et al. 2001, Lapeyre et 
al. 2005, Prince et al. 2002). In such cases, hy-
brid protocols, focusing separately on supra-
genicular and infragenicular arteries, have 
been utilized with good results (Lapeyre et al. 
2005, Owen et al. 2009, Pereles et al. 2006).
MRA has unique limitations. It tends to 
overestimate the degree of stenosis due to 
a loss of signal caused by turbulent blood 
flow and, furthermore, vessel wall calcifi-
cations cannot be evaluated with it (Lee et 
al. 2000). Moreover, susceptibility artefacts 
arising from metallic stents, joint prosthe-
ses and surgical clips can cause signal loss 
within a vessel that mimics stenosis or oc-
clusion (Bartels et al. 2001, Lee et al. 2000, Len-
hart et al. 2000). Indeed, assessing stent pa-
tency and in-stent restenosis is yet an un-
solved challenge with MRA (Lakshminaray-
an et al. 2009).
The high-strength magnetic field utilized 
in MRA excludes patients with implanted 
metallic devices such as cardiac pacemak-
ers, spinal cord stimulators and cochlear 
implants (Hirsch et al. 2006, Norgren et al. 
2007). MRA may also be impossible to per-
form on patients with claustrophobia or co-
operation problems, for the patient has to 
lay still for several minutes for imaging. 
Furthermore, as nephrotoxicity and NSF are 
potential issues with gadolinium, caution is 
advised when administering it for patients 
with chronic renal insufficiency (Penfield et 
al. 2007, Sam et al. 2003).
Computed tomography angiography 
Multi-detector row CTA has been shown 
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PAD, which was demonstrated in, for in-
stance, the meta-analysis by Met et al. in-
cluding 20 studies with a total of 957 pa-
tients (Heijenbrok-Kal et al. 2007, Met et al. 
2009). In a randomized controlled trial by 
Kock et al., 145 patients with PAD were as-
signed for CTA or DSA as the initial imag-
ing modality, and CTA seemed to provide 
sufficient data for clinical decision making 
(Kock et al. 2005). The specificity and sensi-
tivity of CTA for the detection of a steno-
sis of >50% in a lower limb vessel are ap-
proaching those of MRA (Collins et al. 2007, 
Ouwendijk et al. 2005, Met et al. 2009). The 
advantages of CTA are the relatively short 
imaging time and lower cost compared to 
MRA and DSA (Ouwendijk et al. 2005, Ou-
wendijk et al. 2006). The sensitivity for the 
detection of PAD seems to be better with 
CTA than DD (Collins et al. 2007).
Vessel wall calcifications have been re-
ported to be the main reason for the mis-
interpretation of CT angiograms (Ofer et 
al. 2003, Ota et al. 2004). Especially in small-
calibre arteries, the presence of extensive 
vessel wall calcifications makes the produc-
tion of interpretable maximum intensity 
projection images difficult, rendering the 
accuracy of CTA moderate in the calf and 
largely insufficient in calcified pedal arter-
ies (Kau et al. 2011, Ouwendijk et al. 2006). Ad-
ditional disadvantages of CTA include the 
use of ionazing radiation, the use of po-
tentially nephrotoxic iodinated contrast 
media, and the time-consuming three-di-
mensional reconstruction techniques (Ou-
wendijk et al. 2005).
Evaluation of arterial lesion  
severity and extent in infrainguinal PAD
The Bollinger scoring method
The Bollinger scoring method is a means 
of semi-quantitative description of a low-
er limb arterial angiogram (Bollinger et al. 
1981). It was designed for a numerical evalua-
tion of arterial occlusive disease progression 
or regression occurring either spontaneous-
ly or induced by treatment. In the scoring 
method, the infra-aortic arterial tree is di-
vided into ten anatomical segments (Table 
4), and each of the segments is scored sep-
arately according to the severity and extent 
of the disease (Table 5). Four categories of se-
verity of the occlusive lesions are defined: 1) 
occlusion of the lumen, 2) stenosis >50% of 
the luminal diameter, 3) stenosis ≤50% but 
>25%, 4) plaques stenosing the lumen by 
≤25%. Each type of lesion is further catego-
rized by its extent: 1) single lesion, 2) multi-
ple lesions affecting half of the segment or 
less, 3) multiple lesions affecting more than 
half of the segment (Table 5). The numbers 
appearing in the single fields of the scor-
ing matrix correspond to score numbers. 
The additive score is obtained when the in-
dividual scores for the different categories 
of severity are summed in accordance with 
the following rules: 1) in the presence of oc-
Table 4
The arterial segments to which the Bollinger scoring system is applied  
1 Abdominal aorta 6 A. femoralis superficialis
2 A. iliaca communis 7 A. poplitea
3 A. iliaca externa 8 A. tibialis anterior
4 A. iliaca interna 9 A. fibularis
5 A. femoralis profunda 10 A.tibialis posterior
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clusions, plaques or stenoses are not con-
sidered; 2) when both severities of steno-
ses (>50% and ≤50%) are present, plaques 
(≤25%) are not scored; 3) for each type of 
occlusive lesion only one extent category is 
scored. Additionally, in follow-up studies 
changes in occlusion length are taken into 
account – an increase or decrease in the oc-
clusion length of 2 cm adds or diminishes 
the score by 1 point, respectively.
A vectorial score that describes the pat-
tern of the occlusive process can also be cal-
culated with the Bollinger matrix (Table 5). 
The different lesions are coded by their re-
spective numbers appearing in the vertical 
columns. A complete occlusion involving 
not more than half of the segment is indi-
cated in the column for occlusions by the 
number three (3) and a longer occlusion by 
the number five (5). If no number is marked 
in a column, the number zero (0) indicates 
that there is no lesion of this severity. 
TASC
The first TASC document on the manage-
ment of PAD was published in January 
2000 as a result of cooperation between 
fourteen medical and surgical vascular, car-
diovascular, vascular radiology and cardiol-
ogy societies in Europe and North America 
(Hirsch et al. 2006). This comprehensive re-
port included morphological stratifications 
for femoropopliteal and infrapopliteal arte-
rial lesions and recommendations for their 
treatment strategy.
The classifications of different femorop-
oliteal and infrapopliteal arterial lesions ac-
cording to TASC are depicted in Tables 6 and 7. 
This classification has been widely used to 
characterize trial populations and treated le-
sions as well as to report the outcome of a 
specific intervention in lesions of different 
severity, allowing some comparisons to be 
made across studies.
Based on the evidence available at the 
time, the TASC Working Group recom-
mended endovascular treatment as the 
° The vertical columns represent the different severities of atherosclerotic lesions defined.
° The rows represent the extent of disease observed in each segment.
°  The numbers appearing in the single fields correspond to score numbers  
and in practical work  the fields chosen are marked with a cross and the additive  
score is then obtained by summing the numbers marked.
° The vectorial score is obtained by writing the numbers crossed below the vertical columns.
Table 5
The Bollinger scoring matrix (Modified from Bollinger et al. 1981)
Severity
Stenosis Stenosis Plaque
Occlusion > 50 % ≤ 50 % ≤ 25 % Extent of disease
4 2 1 Single lesion
13 5 3 2
Multiple lesions affecting  
half of the segment or less
15 6 4 3
Multiple lesions affecting  
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first-line strategy for lesions of type A and 
open surgery for lesions of type D, but de-
clined to recommend initial treatment for 
type B and C lesions due to insufficient ev-
idence. 
TASC II
The TASC II document was published in 
2007 and is an abbreviated update of the 
original TASC report focusing on key ar-
eas of diagnosis and management of PAD 
(Norgren et al. 2007). Since the publication 
of TASC, advances in expertise in endovas-
cular procedures had led to their common 
use even for TASC C and D lesions with 
satisfying outcomes (Black et al. 2005, De-
Rubertis et al. 2007). Hence, recommenda-
tions for treatment had become outdated 
and TASC II did include revised stratifica-
tions and revascularization recommenda-
tions for femoropopliteal arterial lesions 
(Figure 3). In general, in each TASC II le-
sion category, a more severe morphological 
form of disease is included than in the orig-
inal TASC. Additionally, the TASC II type C 
category includes all new lesion types not 
characterized in TASC. In the TASC II doc-
ument, endovascular therapy was recom-
mended as the treatment of choice for type 
A lesions and bypass surgery for type D le-
sions. Furthermore, depending on co-mor-
bidities, the patient’s preferences and the 
local operator’s long-term success rates, 
endovascular treatment was recommend-
ed as the preferred treatment for type B le-
sions and surgery for type C lesions. No re-
vision was made to the TASC I classifica-
tion of infrapopliteal lesions.
Table 6
TaSC classification of femoropopliteal lesions (Modified from Dormandy et al. 2000) 
Type A
• Single stenosis <3 cm
Type B
• Single stenosis 3–10 cm in length, not involving the distal popliteal artery
• Heavily calcified stenoses ≤3 cm in length
• Multiple lesions, each < cm (stenoses or occlusions)
•  Single or multiple lesions in the absence of continuous tibial runoff to improve  
inflow for distal surgical bypass
Type C
• Single stenosis or occlusion >5 cm
• Multiple stenoses or occlusions, each 3–5 cm, with or without heavy calcification
Type D
•  Complete common femoral artery or superficial femoral artery occlusions or   
complete popliteal and proximal trifurcation occlusions
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Evaluation of outflow
One of the most important predictive tech-
nical factors of bypass graft failure is the 
outflow status of the distal arteries (Albäck 
et al. 1998, Biancari et al. 1999a, Panayitopuolos 
et al. 1997). Its worsening has been shown to 
have a negative effect on the clinical success 
of infrainguinal endovascular interventions 
for CLI as well (Bakal et al. 1990, Davies et al. 
2008, Faglia et al. 2007). Ways of describing 
the outflow have therefore been searched for 
to determine a uniform scoring system that 
would aid in the decision-making when dis-
tal revascularization is planned. The pres-
ence of a completely open or only mildly 
stenosed outflow crural artery, particular-
ly a tibial artery, has been shown to be as-
sociated with improved patency, leg salvage 
and survival after revascularization (Bianca-
ri et al. 1999a, Faglia et al. 2007, Panayitopuo-
los et al. 1997).
Anatomical criteria to define the periph-
eral vascular runoff have been standardized 
by the 1997 revised Society for Vascular Sur-
gery/International Society for Cardiovascu-
lar Surgery (SVS/ISCVS) runoff score (Ruth-
erford et al. 1997; Tables 8 and 9). The corre-
lation of the runoff score with outcome af-
ter revascularization has been tested in nu-
merous studies with mixed results (Albäck 
et al. 1998, Biancari et al. 1999a, Biancari et 
al. 1999b, Davies et al. 2008, Takolander et al. 
1995). However, no better scoring system has 
come along to replace it.  
Treatment of CLI
The management of CLI requires a multi-
disciplinary team of experts in different ar-
Table 7
TaSC classification of infrapopliteal lesions (Modified from Dormandy et al. 2000)
Type A
• Single stenoses <1 cm in the tibial or peroneal vessels
Type B
• Multiple focal stenoses of the tibial or peroneal vessels, each <1 cm in length
• 1 or 2 focal stenoses, each <1 cm long, at the tibial trifurcation
• Short tibial or peroneal stenosis in conjunction with femoropopliteal angioplasty
Type C
• Stenoses 1–4 cm in length
• Occlusions 1–2 cm in length of the tibial or peroneal vessels
• Extensive stenoses of the tibial trifurcation
Type D
• Tibial or peroneal occlusions >2 cm
• Diffusely diseased tibial or peroneal vessels
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The TransAtlantic Inter-Society Consensus for the manage-
ment of peripheral arterial disease (TASC and TASC II1,2)
aims to recommend the preferable methods of revascular-
isation for different arterial lesions by decreasing variation
in the management of individual patients with identical
conditions. The TASC II classification is widely used as
a contemporary guide to aid in decision making concerning
lower limb ischaemia when choosing between endovascular
and surgical techniques. TASC I and II classifications are
used in scientific reports as a means to characterise patient
populations and treated lesions3e5 as well as in reporting
the outcome of a specific intervention in stratified groups
of lesions.6,7 However, the present TASC II classification
may cause confusion, as the grading of lesions can be
cumbersome, allowing individual interpretations of
a number of lesions. This, of course, diminishes the appli-
cability of the classification.
To the best of our knowledge, there are no published
papers on inter-observer agreement on the TASC classifi-
cations. The aim of this study was to evaluate the repro-
ducibility of femoropopliteal TASC II classification between
vascular surgeons and interventional radiologists, in
addition to analysing the influence of an educational
intervention on inter-observer agreement.
Materials and methods
This validation study comprised 200 consecutive angiograms
on femoropopliteal arterial lesions treated with endovas-
cular procedures during 2005e2006 at the Department of
Vascular Surgery at the Helsinki University Central Hospital.
During the first stage, two senior vascular surgeons, two
vascular surgical trainees, two angioradiologists and one
angioradiologist in training evaluated the first 100 angio-
grams independently in one session aided by the TASC II
guide available (Fig. 1). Thereafter, the intervention
included a discussion of the 25 most controversial cases
firstly by a panel of 22 vascular surgeons and vascular
trainees, and, secondly, by the seven investigators in order
to clarify the cases, to agree on TASC II classification
principles and to discuss cases not directly belonging to any
the of TASC II classes. In the second stage, the 100
remaining cases were evaluated independently by the
seven investigators in a manner identical to the first stage.
Figure 1 TASC II classification.
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Figure 3
The TaSC II classification of femoropopliteal arterial lesions.  
Reprinted from the european Journal of Vascular and endovascular Surgery,  
Norgren L, Hiatt wR, Dormandy Ja et al. Inter-society consensus for the management of  
peripheral arterial disease (TaSC II). 2007; 33 Suppl 1: S1-75, with permission from elsevier.
Type A lesions
•  Single stenosis ≤ 
10 cm in length
•  Single occlusion ≤ 
5 cm in length
Type B lesions




•  Single stenosis or 
occlusion ≤ 15 cm 
not involving the 
infrageniculate 
popliteal artery
•  Single or multiple 
lesions in the ab-
sence of continu-
ous tibial vessels 
to improve inflow 
for a distal bypass
•  Heavily calcified 
occlusion ≤ 5 cm 
in lenght
•  Single popliteal 
stenosis
Type C lesions
•  Multiple stenoses 
or occlusions to-
taling > 15 cm with 
or without heavy 
calcification
•  Recurrent steno-
ses or occlusions 
that need treat-




•  Chronic total oc-
clusions of CFA or 
SFA ( > 20 cm, in-
volving the popli-
teal artery)
•  Chronic total oc-
clusions of pop-




eas of vascular disease (Lumsden et al. 2009, 
Norgren et al. 2007). The goals of treat-
ing CLI are to relieve ischaemic pain, heal 
ischaemic ulcers, avoid limb loss, preserve 
mobility, improve the patient’s function-
ing and quality of life, and prolong surviv-
al (Norgren et al. 2007, Varu et al. 2010). Re-
vascularization could optimally reach these 
goals. However, it might not be a viable op-
tion for a number of patients due to severe 
co-morbidities, short life-expectancy, non-
ambulatory status or poor outflow vessels 
in the leg, and for these patients, conserva-
tive treatment or primary amputation might 
be the most appropriate choice of therapy 
(Figure 4). Whichever form of therapy is cho-
sen, the treatment of CLI should always in-
clude modification or elimination of athero-
sclerotic risk factors to slow down the pro-
gression of PAD and to reduce cardiovascu-
lar events, in addition to medical control of 
ischaemic symptoms and infection as well 
as optimization of cardiac and respiratory 
function (Norgren et al. 2007).
Conservative treatment of CLI
Modification of atherosclerotic risk factors 
Diabetes 
It is unclear whether strict glycaemic con-
trol will protect peripheral circulation, im-
prove cardiovascular outcomes or pre-31
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vent amputation (American Diabetes Asso-
ciation, 2006). Nonetheless, it is associat-
ed with sustained decreased rates of reti-
nopathy, nephropathy and neuropathy in 
diabetics (DCCT/EDIC Research Group 2000, 
UK Prospective Diabetes Study [UKPDS] Group 
1998). Additionally, a meta-analysis includ-
ing 9,123 patients by Selvin et al. suggested 
that for every 1% point increase in haemo-
globin A1C (HbA1c), there is a correspond-
ing 26%–28% increase in the risk of PAD 
(Selvin et al. 2004). The American Diabetes 
Association recommends HbA1c of <7% as 
the goal for the treatment of diabetic pa-
tients in general, but a level as close to nor-
mal (<6%) as possible without significant 
hypoglycaemia should be the target for the 
individual patient (American Diabetes Asso-
ciation 2006).    
Smoking cessation
For a patient with PAD the risk of death, 
cardiovascular events and amputation 
seems to be substantially greater in those 
individuals who smoke than in those who 
stop smoking (Jonason et al. 1987, Faulkner 
et al. 1983, Lepäntalo et al. 1991). Smoking al-
so has a negative effect on bypass graft pa-
tency, as continued smoking after lower 
limb bypass surgery was shown to result 
in a threefold increased risk of graft fail-
ure in a meta-analysis including 29 stud-
Table 8
Resistance values of runoff arteries according to SVS/ISCVS  
(Modified from Rutherford et al. 1997)
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ies by Willigedael et al. (Willigedael et al. 
2005). A systematic review by Critchley et 
al. consisting of 20 studies with a total of 
12,603 patients indicated that smoking ces-
sation may have a greater effect on reduc-
ing the risk of mortality among patients 
with CAD who smoke than any other inter-
vention or treatment (Critchley et al. 2003). 
Consequently, the cessation of smoking is 
a cornerstone in the management of PAD 
at any stage.
Dyslipidaemia
A multicentre randomized controlled trial 
(RCT) with 20,536 patients, The Heart Pro-
tection Study (HPS), showed that the use of 
statins to lower LDL cholesterol has a pro-
tective effect in patients with PAD, as it re-
*  When calculating the runoff score for above-knee popliteal recipient artery,  
either popliteal above the knee(AK) or popliteal below the knee (BK) can be used,  
whichever offers the highest degree of resistance.
Table 9
Calculation of the SVS/ISCVS runoff score for infrainguinal revascularizations 
(Modified from Rutherford et al. 1997)
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sulted in a 22% relative reduction in major 
cardiovascular events during the 5-year fol-
low-up (Heart Protection Study Collaborative 
Group 2000). Statin use also seems to reduce 
mortality in patients with CLI in particular; 
this was demonstrated by analyzing the co-
hort of The PRoject of Ex-Vivo vein graft EN-
gineering via Transfection (PREVENT III, 
PIII), a multicentre RCT comprising 1,404 
CLI patients undergoing infrainguinal by-
pass surgery (Schanzer et al. 2008a). For all 
symptomatic PAD patients, the target val-
ue for LDL is <2.5 mmol/l and <1.8 mmol/
l for those with PAD and a history of vascu-
lar disease in other beds, i.e., CAD (Hirsch 
et al. 2006). The target value for total choles-
terol is <4.5 mmol/l (DeBacker et al. 2003). 
No specific treatment goals were defined for 
HDL cholesterol or triglycerides, but con-
centrations of HDL cholesterol <1.0mmol/l 
and fasting triglycerides >1.7mmol/l, seem 
to serve as markers of increased cardiovas-
cular risk (DeBacker et al. 2003). 
Hypertension
Hypertension is associated with a two to 
three-fold increased risk for PAD, and the 
treatment of high blood pressure prevents 
the occurrence of cardiovascular disease 
morbidity and mortality (Chobanian et al. 
2003, Norgren et al. 2007, Psaty et al. 2003). 
The current recommendation is that blood 
pressure should be lowered at least to be-
low <140/90 and even lower, if tolerated, 
in all hypertensive patients. Furthermore, 
a blood pressure level of <130/80 should be 
pursued, if the patient has diabetes, chronic 
renal disease or CVD and considered in pa-
tients with CAD (Chobanian et al. 2003, Man-
cia et al. 2007). 
Antithrombotic therapy
The Antithrombotic Trialists’ Collaboration 
(ATC) meta-analysis comprised 287 stud-
ies involving 135,000 patients in compari-
sons of antiplatelet therapy versus control 
and 77,000 in comparisons of different an-
tiplatelet regimens, and it showed a sig-
nificant reduction in MI, stroke and death 
with antiplatelet therapy in all patients with 
symptomatic cardiovascular disease. The 
study included a subset analysis on patients 
with PAD among whom a reduction of car-
diovascular events was demonstrated with 
antiplatelet therapy (Antithrombotic Trial-
ists’ Collaboration 2002). According to cur-
rent guidelines, lifelong aspirin therapy (75 
to 325 mg/day) is recommended for all pa-
tients with PAD instead of no antiplatelet 
therapy (Clagett et al. 2004, Norgren et al. 
2007). 
The TASC II document recommends an-
tiplatelet therapy after an endovascular or 
surgical procedure and states further that it 
should be initiated preoperatively and con-
tinued as adjuvant pharmacotherapy indef-
initely unless subsequently contraindicat-
ed (Norgren et al. 2007). Aspirin is recom-
mended for patients undergoing prosthet-
ic infrainguinal bypass or PTA (Clagett et 
al. 2004). Warfarin is additionally an alter-
native for patients undergoing infraingui-
nal bypass with a venous graft, but this is 
accompanied by an increased risk of major 
bleeding episodes (Dutch Bypass Oral Antico-
agulants or Aspirin (BOA) Study Group 2000, 
Norgren et al. 2007). Direct thrombin inhib-
itors, such as dabigatran, are an emerging 
new group of anticoagulants that may be 
used as an alternative to warfarin (Connol-
ly et al. 2009). Clinical trials on their use in 
PAD are, however, still lacking.
The combination of aspirin and clopido-
grel has been demonstrated to be superior 
to aspirin alone in preventing adverse car-
diovascular events in patients undergoing 
percutaneous coronary intervention, pa-
tients with acute coronary syndromes with-
out ST-segment elevation, and patients with 
ST-elevation MI (Chen et al. 2005, Mehta et al, 
2001, Yusuf et al. 2001). This dual antiplate-
let therapy is nowadays applied for at least 34
1 month after infrainguinal stent implanta-
tion in all major endovascular centres and 
ongoing stenting trials on the basis of da-
ta from the coronary field (Schillinger et al. 
2007). In the Clopidogrel and Acetylsalicyl-
ic Acid in Bypass Surgery for Peripheral Ar-
terial Disease (CASPAR) study, a multicen-
tre RCT with 851 patients, the same dual an-
tiplatelet therapy was compared to aspirin 
alone in PAD patients undergoing bypass 
surgery, and no improvement in limb or 
systemic outcomes in the overall population 
was reached with the dual antiplatelet ther-
apy. However, a post hoc subgroup analysis 
suggested that the dual antiplatelet therapy 
offered a benefit for patients receiving pros-
thetic grafts without significantly increasing 
major bleeding risk (Belch et al. 2010).
Other medical and  
pharmacological treatment of CLI
Although some previous studies have sug-
gested improved healing of ischaemic ul-
cers and reduction in amputation when 
treating CLI patients with prostanoids, 
their use have failed to modify the amputa-
tion rate in recent studies (Brass et al. 2006, 
Norgren et al. 2007, UK Severe Limb Ischaemia 
Study Group 1991). The prediction of response 
to prostanoids is difficult, and they are rare-
ly used in the treatment of CLI (Norgren et 
al. 2007).
Spinal cord stimulation (SCS) seems to be 
a possible treatment option for patients suf-
fering from inoperable CLI. A meta-analysis 
of six contolled trials with 444 patients dem-
onstrated a significant improvement in leg 
salvage for those CLI patients treated with 
SCS when compared to those treated with 
optimum medical treatment. In addition, 
patients treated with SCS required signifi-
cantly fewer analgesics and showed a sig-
nificant clinical improvement. The authors 
concluded, however, that the positive effects 
of SCS should be weighed against the high 
cost and possible complications (Ubbink et 
al. 2006). SCS is not widely used for CLI.  
Invasive treatment of CLI
Revascularization offers the best chance 
of leg salvage for CLI patients. Traditional-
ly, bypass surgery with an autogenous vein 
has been considered the approach of choice 
to avoid amputation and is still regarded 
the gold standard for the treatment of CLI 
(Hirsch et al. 2005, Mills, 2005). However, by-
pass surgery is a demanding and potential-
ly dangerous operation for the CLI patient, 
with a perioperative mortality rate ranging 
from 1% to 2% and postoperative wound 
complications affecting approximately 20% 
of the patients (Norgren et al. 2007, Slovut and 
Sullivan, 2008). Therefore, the less invasive 
endovascular techniques, such as PTA, have 
gained acceptance as a treatment method 
for CLI in recent years. Although they per-
form inferiorly to bypass surgery in terms 
of patency, the leg salvage rates are compa-
rable (Eskelinen et al. 2005, Faglia et al. 2005, 
Romiti et al. 2008; Tables 10 and 11). Indeed, 
in the past decade the number of endovas-
cular interventions for leg salvage has in-
creased dramatically (Kudo et al. 2006). The 
continuous improvement of endovascular 
techniques and devices has made more and 
more complex lesions amenable to the en-
dovascular approach, and in some centres, 
the endovascular approach has even sup-
planted bypass surgery as the first-choice 
revascularization method (Baril et al. 2010, 
Haider et al. 2006, Kudo et al. 2006). 
Basic principles of infrainguinal revascularization
Bypass surgery
The surgical means of treating CLI is to cre-
ate a bypass over the diseased, occluded ar-
terial segment. Prior to the operation, unim-
peded proximal arterial inflow must be en-
sured. Thereafter, the take-off level of the by-
pass graft (i.e., common femoral artery, su-
perficial femoral artery [SFA] or popliteal ar-35
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tery) does not seem to correlate with patency 
(Norgren et al. 2007). The good quality of the 
outflow artery is also an important determi-
nant of patency, whereas the level of distal 
anastomosis is of lesser importance. In gen-
eral, the the most proximal artery provid-
ing continous runoff to the foot should be 
selected as the primary target (Conte 2010b, 
Norgren et al, 2007).
The type of conduit is an important factor 
affecting the success of infrainguinal bypass 
surgery. The great saphenous vein (GSV) is 
considered the most durable conduit for in-
frainguinal revascularization. Alternative 
(i.e., arm veins or the lesser saphenous vein) 
and spliced vein grafts have been shown to 
perform inferiorly to single-segment GSV 
(Faries et al. 2000, Londrey et al. 1994). How-
ever, all vein grafts fare significantly better 
in comparison to prosthetic grafts, especial-
ly when the revascularization extends infra-
genicularly (Klinkert et al. 2003, Norgren et 
al. 2007, Pereira et al. 2006).
The vein graft may be implanted in a re-
versed, non-reversed or in-situ bypass fash-
ion, which produce comparable patency 
rates (Belkin et al. 1996, Shah et al. 1995, Tay-
lor et al. 1990). In some circumstances, it 
may be advantageous to select one config-
uration over the other – i.e., to optimize ar-
tery-vein size match.   
Endovascular revascularization
PTA is the traditional means of infraingui-
nal endovascular revascularization. A con-
tralateral retrograde or an ipsilateral ante-
grade femoral access are most commonly 
used. The arterial lesion is crossed with a 
Table 10
Leg salvage rates after infrainguinal revascularization for CLI
Study  B: vein graft
type 1 year 3 years 5 years 10 years E: stent
Conte et al. 2006 P M 1404 88 (-) − − − B: 100%
Pomposelli et al. 2003 R S 1032 − − 78 (-) 58 (-) B: 99.8%
Söderström et al. 
2010
R S 636 83 (2) 80 (3) 76 (2) − B: 90%
Kudo et al. 2006 R S 75 − − 74 (-) − B: 59%
Biancari et al. 1999a R S 77 80 (-) 76 (-) − − B: 15%
Jämsén et al. 2002 P S 116 68 (5) 65 (5) 60 (6) − E: None
Kudo et al. 2006 R S 105 − − 91 (-) − E: 2%
Conrad et al. 2011 R S 447 88 (2) 84 (2) 74 (4) − E: 26%
Söder et al. 2000 P S 72 80 (5) − − − E: None
Scott et al. 2008 R S 265 88 (2.5) 75 (5.9) − − E: 20%
Eskelinen et al. 2005 R S 230 92 (-) − − − E: 2%
Author
M=multicentre; S=single centre; R=retrospective; P=prospective; N=number of limbs;
B=bypass; E=endovascular      
N Leg salvage % (±SE)
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guidewire, and a balloon is inflated to dila-
tate the stenosed/occluded arterial segment. 
Heparinization during the intervention is 
standard treatment (Norgren et al. 2007).
The severity of limb ischaemia and the 
outflow status of distal arteries affect the 
outcome of PTA (Davies et al. 2008). Fur-
thermore, the lesion complexity (i.e., lesion 
length, stenosis vs. occlusion and TASC II 
classification) and multilevel interventions 
have been shown to affect the outcome of 
endovascular interventions (DeRubertis et al. 
2007, Lazaris et al. 2006).
TASC II recommends stent placement 
when PTA of a SFA lesion fails acutely (Nor-
gren et al. 2007). Even though there are prom-
ising intermediate-term results from prima-
ry stenting of SFA lesions, the current data 
does not support routine stenting over selec-
tive stenting (Kasapis et al. 2009, Schillinger 
et al. 2006, Twine et al. 2009). There are many 
emerging catheter-based technologies such 
as laser atherectomy, drug-eluting balloons 
and drug-eluting stents (Duda et al. 2006, Laird 
et al. 2006, Zeller et al. 2011). Their role in the 
treatment of CLI is not yet established.   
On choosing the revascularization strategy for CLI
There is no uniform treatment algorithm 
for CLI, and controversy prevails in regard 
37
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Table 11
Meta-analysis results of crural PTa and popliteal-to-distal bypass 
(Modified from Romiti et al. 2008).
Result 1 month 6 months 1 year 2 years 3 years
Primary patency
    PTA 77.4 ± 4.1 65.0 ± 7.0 58.1 ± 4.6 51.3 ± 6.6 48.6 ± 8.0
    Bypass 93.3 ± 1.1 85.8 ± 2.1 81.5 ± 2.0 76.8 ± 2.3 72.3 ± 2.7
    p-value <0.05 <0.05 <0.05 <0.05 <0.05
Secondary patency
    PTA 83.3 ± 1.4 73.8 ± 7.1 68.2 ± 5.9 63.5 ± 8.1 62.9 ± 11.0
    Bypass 94.9 ± 1.0 89.3 ± 1.6 85.9 ± 1.9 81.6 ± 2.3 76.7 ± 2.9
    p-value <0.05 <0.05 <0.05
Leg salvage
    PTA 93.4 ± 2.3 88.2 ± 4.4 86.0 ± 2.7 83.8 ± 3.3 82.4 ± 3.4
    Bypass 95.1 ± 1.2 90.9 ± 1.9 88.5 ± 2.2 85.2 ± 2.5 82.3 ± 3.0
Survival
     PTA 98.2 ± 0.7 92.3 ± 5.5 87.0 ± 2.1 74.3 ± 3.7 68.4 ± 5.5
    Bypass NA NA NA NA NA
NA, not available     
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to whether the first-line revascularization 
strategy should be surgical or endovascu-
lar. There are numerous studies promot-
ing the advantages of either strategy, but al-
most all of them are flawed due to, for in-
stance, retrospective analysis, no random-
ization, a small number of patients or data 
derived from a single centre. In the TASC 
II document, previous outcome data were 
applied to identify the location and types of 
femoropopliteal arterial lesions best treated 
by endovascular or open approaches (Nor-
gren et al. 2007). These recommendations 
provided strong evidence only for the mild-
est and most severe disease patterns (type A 
and D lesions), but the choice of treatment 
strategy for managing type B and C lesions 
were still left essentially to the physician’s 
preference.
At present there is only one large multi-
centre RCT comparing the two revascular-
ization methods – the Bypass versus Angio-
plasty in Severe Ischaemia of the Leg (BA-
SIL) trial, in which 452 patients presenting 
with severe leg ischaemia (SLI) due to in-
frainguinal disease were randomised to re-
ceive either bypass surgery or PTA as first-
line treatment strategy (Adam et al. 2005). The 
patients were included in this series on the 
basis of having clinical symptoms of chronic 
limb ischaemia (Rutherford categories 4–6, 
Fontaine stages III–IV) of presumed arterial 
aetiology, hence regardless of AP measure-
ments. Therefore, the broader term SLI was 
used, as the objective pressure criteria rec-
ommended by, e.g., TASC were not utilized. 
In the short term, the PTA first-strategy was 
associated with significantly lower morbid-
ity, initial cost and shorter hospital stay. On 
the other hand, in the long term after 2 
years, there was a significant improvement 
in survival and a trend toward improved am-
putation-free survival (AFS) in favour of the 
surgery first-strategy. Overall, there was no 
significant difference in cost between the 
two treatment strategies, as the re-interven-
tion rate was higher after PTA. Neither was 
there a difference in the overall health-relat-
ed quality of life (Adam et al. 2005, Bradbury 
et al. 2010a, Bradbury et al. 2010b). Previous 
studies have suggested that attempted PTA 
does not jeopardize the chances of a subse-
quent bypass surgery; however, in the as-
treated analysis of the BASIL trial, a reduced 
AFS was observed for those who underwent 
bypass surgery after failed PTA when com-
pared to those who received bypass surgery 
as the initial therapy (Bradbury et al. 2010b, 
Ryer et al. 2006, Sandford et al. 2007). Fur-
thermore, AFS was reduced for those who 
received a prosthetic graft when compared 
to those who received a venous graft among 
the patients who underwent bypass surgery 
as the initial treatment method (Bradbury et 
al. 2010b).
Therefore, the results of the BASIL trial 
suggested that those CLI patients surviving 
≥ 2 years, and with a useable vein, are prob-
ably better served by bypass surgery as the 
first-line strategy. Furthermore, the patients 
who are expected to live < 2 years or those 
without an available vein are probably better 
served by PTA as the first-line strategy.   
Amputation
Major amputation is indicated in CLI pa-
tients when there is a life-threatening in-
fection involving the ischaemic leg, when 
rest pain cannot be controlled, when ex-
tensive necrosis has destroyed the foot, or 
when the pattern of arterial disease is con-
sidered unsuitable for a revascularization at-
tempt (Norgren et al. 2007). Primary amputa-
tion should also be considered if the CLI pa-
tient has a very limited life expectancy, ter-
minal illness, dementia, dependent living 
status or is chronically bed-ridden (Biancari 
et al. 2000, Nehler et al. 2004, Norgren et al. 
2007, Taylor et al. 2009, Varu et al. 2009).
Secondary amputation is indicated when 
vascular intervention is no longer possible, 
when the limb deteriorates despite a patent 38
reconstruction, or where there is persistent 
infection despite reconstruction attempts 
(Norgren et al. 2007).      
Outcome prediction models 
The outcome of reconstructed and unrecon-
structed CLI can be rather poor (Adam et al. 
2005, Lepäntalo et al. 1996). It has been sug-
gested that lower limb revascularization is 
worth the endeavour if there is reasonable 
probability that the patient will remain alive 
with an intact index limb at 1 year (Second 
European Consensus Document 1991). Estima-
tion of the risk of poor post-operative out-
come is of great clinical and economical im-
portance when invasive procedures for the 
treatment of CLI are being considered. It is 
evident that the nature of failed lower limb 
revascularization is largely multi-factorial, 
as during the last decades a number of risk 
factors associated with poor outcome have 
been identified. Outcome prediction models 
have been developed to, for instance, guide 
the clinician in deciding on the optimal re-
vascularization method and identify the pa-
tients whose poor outcome estimates sug-
gest a conservative approach (Arvela et al. 
2010, Biancari et al. 2007, Bradbury et al. 2010d, 
Schanzer et al. 2008b).
The Finnvasc risk score
The Finnvasc risk scoring method was orig-
inally developed to predict 30-day post-oper-
ative mortality and/or major lower limb am-
putation in patients undergoing infraingui-
nal surgical revascularization for CLI (Bian-
cari et al. 2007). Since then, this method has 
been shown to be useful in the estimation 
of immediate and long-term post-procedur-
al outcome of patients undergoing infrain-
guinal bypass surgery or PTA for CLI (Arve-
la et al. 2010, Kechagias et al. 2008). 
The basis of this method was derived from 
the data on 3,925 CLI patients who under-
went infrainguinal surgical revasculariza-
tion extracted from the Finnvasc Registry. 
The Finnvasc Registry was a nation-wide 
vascular registry to which 25 Finnish hospi-
tals prospectively entered data on surgical 
procedures during 1991–1999 (Salenius et 
al. 1992). In this model diabetes, CAD, gan-
grene and urgent operation are independent 
risk factors for adverse post-operative out-
come. The risk score for each patient is the 
number of these risk factors present. There 
was a significant association between high 
scores and adverse immediate post-opera-
tive outcome, and this was particularly true 
for a risk score ≥3 (Biancari et al. 2007). 
The PIII risk score  
The PIII risk score can be used to estimate 
the 1-year AFS in CLI patients considered 
for infrainguinal revascularization (Arve-
la et al. 2010, Schanzer et al. 2008b, Schanzer 
et al. 2009). This prediction model was de-
rived from the cohort of patients who un-
derwent open infrainguinal bypass surgery 
for CLI in the context of the PIII RCT (Con-
te et al. 2005). In this model, points are as-
signed to each patient for the presence of di-
alysis (4 points), tissue loss (3 points), age 
≥75 (2 points), anaemia (hematocrit ≤30, 2 
points) and advanced CAD (1 point), which 
were all found to be significant predictors 
of poor AFS at 1 year post-operatively. The 
PIII risk score is calculated by adding the 
yielded points together. On the basis of the 
score, the patients can be stratified in three 
risk categories: low (≤3 points), medium (4–
7 points) and high (≥8 points; Figure 5). 
The BASIL survival prediction model
The results from the BASIL trial suggest 
that CLI patients surviving >2 years are 
best served by bypass surgery as the first-
line revascularization strategy rather than 
PTA (Bradbury et al. 2010a). Accordingly, a 
survival prediction model was created to 
estimate the chances of survival >2 years 
(Bradbury et al. 2010d). The 452 SLI patients 
who underwent infrainguinal revasculariza-39
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tion in the context of the BASIL multicen-
tre randomised trial formed the basis of this 
model. The factors that contributed to the 
Weibull predictive model were age, tissue 
loss, serum creatinine, number of AP mea-
surements detectable, maximum AP mea-
sured, CAD, CVD, below the knee Bollinger 
score, body mass index, and smoking sta-
tus. The survival probability for each patient 




The PIII Score card (Modified from Schanzer et al. 2008)
Am
putation-free survival rates (%
)
Low risk:  
≤ 3 points
Medium risk: 
4 – 7 points

















1.  To compare the outcomes of infrainguinal  
PTA and bypass surgery for CLI
 
2.  To assess the predictors of poor outcome after  
infrainguinal PTA for CLI
3.  To evaluate the reproducibility of the TASC II  
classification for femoropopliteal arterial lesions
4.  To evaluate the communication between  
interventional radiologists and vascular surgeons  
when treating patients with CLI ❦
Aims of the study
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Studies I–III
Patients and data collection 
A total of 2,054 CLI patients underwent infrainguinal lower limb re-
vascularization at the Helsinki University Central Hospital between 
2000 and 2007. Data on these procedures were systematically col-
lected in our institutional database (HUSVasc registry) and scruti-
nized retrospectively. Of these patients, 858 underwent unilateral 
femoropopliteal revascularization, constituting the study population 
of Study I. In this group, PTA was performed on 517 (60%) and by-
pass surgery on 341 (40%) patients.
The patient population of Study II was composed of the 1,023 CLI 
patients on whom unilateral revascularization extending into the 
infrapopliteal arteries was performed during the study period. Of 
them, 262 (26%) underwent PTA and 761 (74%) bypass surgery. 
The patient population of Study III consisted of the 217 consecu-
tive patients with 240 chronic critically ischaemic limbs treated with 
infrainguinal PTA between January 2006 and December 2007.
The data recorded in our institutional database included preoper-
ative patient data such as co-morbidities, risk factors for PAD, indi-
cation for the revascularization as well as ABI and/or TP measure-
ments. Additionally, operative details – such as urgency of the pro-
cedure, procedure code and graft material as well as postoperative 
data concerning graft patency, clinical outcome and possible com-
plications and re-interventions – were noted. Dates of death were re-
trieved from Finnish national registry (Statistics Finland). Data on 
late major lower amputations and re-interventions have been com-
pleted retrospectively from the files of the National Research and 
Development Centre for Health and Welfare.
Arterial lesions were classified according to the TASC II docu-
ment. The angiographic status of the runoff vessels was determined 
at the site of angioplasty/distal anastomosis 
downward, and the run-off score was calcu-
lated according to the SVS/ISCVS criteria 
from the completion angiogram.  In addi-
tion, angiographic runoff was categorized in 
terms of target vessel patency, also termed 
as in-line open continuation down to the 
pedal arteries (I and II).
All cases and angiographies were re-
viewed and discussed at the daily integrat-
ed vascular meetings of vascular surgeons 
and interventional radiologists for decision-
making on the revascularization method.     
Endovascular revascularization 
All endovascular procedures were performed 
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PTA was the preferred method. Stents were 
placed selectively in cases with immediate 
unsatisfactory results. A stent was placed in 
3% of the primary interventions in the study 
population of Studies I and III. No stents 
were placed in infrapopliteal arteries.
Surgical revascularization
Non-reversed vein grafts were mostly used. 
Because of the lack of suitable veins, a pros-
thetic graft had to be utilized in 21% of the 
patients in Study I and in 6% of the patients 
in Study II. 
Antithrombotic regimen
After a successful endovascular interven-
tion, the patients were put on dual antiplate-
let therapy of clopidogrel and aspirin for at 
least 1 month, after which they were pre-
scribed lifelong aspirin, with the exception 
of those who were already on continued an-
ticoagulation before revascularization. 
After bypass surgery, the patients received 
low molecular weight heparin during their 
post-operative hospital stay, in addition to 
aspirin which was continued indefinitely. 
Follow-up
All patients were followed until their symp-
toms subsided and/or wounds healed. After 
endovascular revascularization, the routine 
follow-up consisted of one clinical examina-
tion and ABI measurement at one month af-
ter the procedure, whereas bypass surgery 
patients were followed by a clinical exami-
nation, ABI measurement and DD scan at 
1, 6 and 12 months routinely. In the endo-
vascularly treated patient group, a DD scan 
was performed only if necessitated by the 
clinical situation.
Outcome endpoints
In Studies I and II, overall survival, major 
lower limb amputation, (major) AFS, free-
dom from any further re-intervention (in-
cluding all open and endovascular re-inter-
ventions performed to maintain the origi-
nal revascularization and redo-procedures 
performed due to occlusion of the original 
revascularization) and freedom from surgi-
cal re-intervention (redo-bypass, i.e., bypass 
that comprises more than half of the graft) 
were the main outcome measures. 
In Study III, the primary outcome mea-
sures were death, (major) amputation and 
the need for secondary bypass surgery with-
in 6 months after the primary endovascu-
lar procedure. The secondary outcome mea-
sures were the overall survival and (major) 
amputation rate, the overall need for sec-
ondary bypass surgery, the overall need for 
any re-intervention and the need for endo-
vascular re-intervention. 
Study IV
The study material consisted of 200 prepro-
cedural angiograms of CLI patients under-
going a femoropopliteal endovascular inter-
vention at the Helsinki University Central 
Hospital during 2005–2006.
During the first study phase, seven in-
vestigators (two senior vascular surgeons, 
two vascular surgical trainees, two angio-
radiologists and one angioradiologist in 
training) independently categorized the 
femoropopliteal lesions on the first 100 
angiograms according to the TASC II doc-
ument on hand. After this, two interven-
tion sessions were carried out; the first was 
a discussion of the 25 most controversial 
cases by a panel of 22 vascular surgeons 
and vascular trainees, and in the second 
session the seven original investigators 
sought agreement on the TASC II classifi-
cation philosophy and discussed the prin-
ciples of categorizing those arterial lesions 
not directly belonging to any of the TASC 
II classes.
Thereafter, in the second phase of the 
study, the remaining 100 angiograms were 
evaluated by the same seven investigators in 
a manner similar to the first phase. 46
Study V 
In 2007, a total of 351 patients with CLI were 
referred by vascular surgeons to the Depart-
ment of Radiology for DSA or an endovas-
cular procedure at the Helsinki University 
Central Hospital. These referrals were scru-
tinized retrospectively.
The quality of the referral was assessed 
for the adequacy of description of the pa-
tient’s clinical situation. This was evaluat-
ed by recording whether the referral text 
included the indication for the DSA, pulse 
palpation status, ABI and/or TP measure-
ments. Data were gathered on whether the 
clinician wished for 1) DSA only, 2) endovas-
cular intervention to treat a lesion on the ba-
sis of other vascular imaging or 3) DSA, and 
in case of a suitable arterial lesion, addition-
ally an endovascular intervention.
 On the other hand, the execution of this 
request by the interventional radiologist was 
evaluated. If the request and execution dif-
fered from each other, the reason for this 
was recorded as well as whether a vascu-
lar surgeon was a co-operator in the proce-
dure or had been consulted prior to the in-
tervention. 
Statistical methods
In all studies, except for Study IV, the data 
were statistically analyzed using SPSS (Sta-
tistical Package for Social Sciences, SPSS 
Inc, Chicago, IL, USA) software. 
In Studies I and II, propensity score anal-
ysis was used to reduce bias when calculat-
ing the effect of the treatment. Pearson’s 
chi square test, Fisher exact test and Mann-
Whitney test were used for univariate analy-
sis. Logistic regression with backward selec-
tion was performed to calculate the risk, the 
so-called propensity score, of the patients to 
be included either in the PTA or bypass sur-
gery group. Hosmer-Lemeshow’s test was 
used to assess the regression model fit. Vari-
ables having a p<0.2 at univariate analysis 
were included in the regression model. Re-
ceiver operating characteristic (ROC) curve 
analysis was used for estimation of the area 
under the curve of the model predicting the 
probability of being included into the PTA 
or bypass surgery group.
The calculated propensity score was used 
for risk adjustment in multivariable analy-
sis and for one-to-one matching.  One-to-one 
propensity score matching between study 
groups was done according to a difference in 
the propensity score of < 0.005. Cox regres-
sion with the help of backward selection was 
used to adjust the effect of treatment meth-
od on propensity score as well as other vari-
ables in evaluating continuous outcome end-
points. Long-term outcome was assessed by 
the Kaplan-Meier’s method with the log-rank 
test and the Cox regression method. Out-
come in the propensity-matched pairs was 
evaluated by Kaplan-Meier’s methods as well 
as the Cox regression method. A p<0.05 was 
considered statistically significant.
In Study III, the predictors of primary and 
secondary endpoints were identified with a 
univariate screen using p < 0.2 as a thresh-
old for inclusion in the multivariate analy-
ses. A Cox regression model with enter se-
lection was used in the multivariate analy-
sis for the outcome endpoint measures. Ka-
plan-Meier survival curves were utilized to 
describe the differences in survival with as-
sociated factors.
In Study IV, a multi-observer variation of 
Brennan and Brediger’s free marginal kap-
pa (κfree) was used to calculate a change-ad-
justed measure of agreement using the On-
line Kappa Calculator (www.justusrandolph.
net/kappa). Values of κfree can range from 
-1.0 to 1.0, with -1.0 indicating perfect dis-
agreement below chance, 0.0 indicating 
agreement equal to chance and 1.0 indicat-
ing perfect agreement above chance. A κfree 
of 0.70 or above was considered to indicate 
adequate inter-observer agreement.
In Study V, Chi-square test was used to 
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Studies I and II
The overall patient series
The baseline clinical characteristics and operative data of the study 
populations are given in Table 12. The mean length of follow-up 
was 2.6±2.2 years.
Study I. The leg salvage rates of the overall population at 30-day, 
1-year, 3-year and 5-year intervals were 98.0%, 90.1%, 85.9% and 
83.3%, respectively. At the same intervals, the respective survival 
rates were 96.8%, 78.2%, 61.2% and 52.2%, and the respective AFS 
rates were 94.4%, 73.9%, 55.6% and 46.3%. Further revasculariza-
tion procedures were required for 111 (21.5%) patients in the PTA 
group and for 63 (18.5%) patients in the bypass surgery group.
Study II. Leg salvage rates of the overall population at 30-day, 1-
year, 3-year and 5-year intervals were 94.4%, 83.0%, 78.9% and 
75.9%, respectively. At the same intervals, the respective survival 
rates were 94.8%, 75.1%, 56.3% and 44.1%, and the respective AFS 
rates were 90.1%, 65.6%, 47.8% and 37.2%. Further revasculariza-
tion procedures were required for 48 (18.3%) patients in the PTA 
group and for 159 (20.9%) patients in the 
bypass surgery group.
PTA versus bypass surgery  
in the overall patient series
PTA had poorer long-term results than by-
pass surgery in the femoropopliteal seg-
ment; there was a significant difference 
in survival (49.2% vs. 57.1%, p=0.048), 
AFS (42.0% vs. 53.7%, p=0.003) and leg 
salvage (78.2% vs. 91.8%, p<0.0001) at 
5 years in favour of the bypass surgery 
group. On the other hand, the long-term 
results achieved with PTA and bypass 
surgery extending to the infrapopliteal 
Results
49
The effectiveness of infrainguinal 
percutaneous transluminal angioplasty in 
the treatment of critical limb ischaemia
50
Table 12











































































































































































































































































































































































































































































































































































     
     
     
     
     
     
     
     
     
     
     
     
     
     
     



































































































The effectiveness of infrainguinal 
percutaneous transluminal angioplasty in 




















































































































































































































































































































































































































































































































































segment were similar in both treatment 
groups in terms of survival, AFS and leg 
salvage (Table 13).
Freedom from any re-intervention did not 
differ between the PTA and bypass surgery 
group infrainguinally, but freedom from 
surgical re-intervention was significantly 
lower after PTA at 5 years (Table 13).
The propensity score analysis
Patients treated with PTA had more co-mor-
bidities compared to those treated with by-
pass surgery. In both Studies I and II, the 
patients in the PTA group were significantly 
more likely to have diabetes and renal insuf-
ficiency. The status of the run-off vessels was 
also significantly poorer in the PTA group in 
both studies; the PTA patients had less fre-
quently a patent target vessel down to the 
pedal arteries and, additionally, in Study I 
the runoff-score was worse compared to the 
bypass surgery group.
As the study groups differed markedly 
from each other in their observed covari-
ates, the propensity score was calculated to 
estimate the risk of these patients to under-
go either PTA or bypass surgery. Variables 
included in the logistic regression model 
for the calculation of the propensity score 
in Study I were age, sex, diabetes, cerebro-
vascular disease, pulmonary disease, smok-
ing, previous lower limb revascularization, 
chronic kidney disease class according to es-
timated glomerular filtration rate (eGFR), 
tissue loss, runoff score and patent target 
vessel down to the pedal arteries. In Study 
II, these were age, diabetes, hypertension, 
hyperlipidemia, cerebrovascular disease, 
pulmonary disease, smoking, previous re-
vascularization of the same arterial seg-
ment, eGFR, indication for revasculariza-
tion, patent target vessel down to the pedal 
arteries and procedure target level.
The obtained propensity score had an ar-
ea under the ROC curve of 0.73 (95% con-
fidence interval (CI) 0.70–0.76, p<0.0001) 
in Study I and 0.82 (95% CI 0.79–0.84, 
p<0.001) in Study II.
PTA versus bypass surgery according  
to propensity score analysis
In the overall series, when treatment meth-
od was adjusted for propensity score, PTA 
was associated with significantly poorer leg 
salvage (p=0.020, risk ratio (RR) 1.81, 95% 
CI 1.10–2.97) when the femoropopliteal 
segment was treated. However, when pro-
cedures extending to the infrapopliteal seg-
ment were performed, leg salvage did not 
differ significantly between the treatment 
groups (p=0.19). There was no significant 
difference between the treatment groups 
in either study in terms of survival, AFS or 
freedom from any re-intervention when ad-
justed for propensity score. Nonetheless, in 
both studies freedom from surgical re-in-
tervention was significantly lower for the 
PTA group.
One-to-one propensity score matching 
provided 241 pairs of patients in Study I and 
208 pairs of patients in Study II who under-
went either PTA or bypass surgery (Table 14). 
The late outcome estimates in the propensity 
score matched pairs are shown in Table 15.
During the five-year follow-up, PTA was 
associated with significantly poorer leg sal-
vage in the matched-pairs analysis (74.3 % 
vs. 88.2%, p=0.031) when the femoropopli-
teal level was treated, but no significant dif-
ference was observed in terms of leg sal-
vage between the study groups when the 
infrapopliteal level was also treated (74.4% 
vs. 69.3% for PTA and bypass respective-
ly, p=0.11). However, PTA and bypass sur-
gery achieved similar rates of survival, AFS 
and freedom from any re-intervention in the 
long term in both studies. In the matched-
pairs analysis, the freedom from surgical 
re-intervention was significantly lower in 
the PTA group in both studies (at 5 years; 
Study I: 86.1% vs. 89.8%, p=0.025; Study 
II: 85.3% vs. 91.4%, p=0.05). 52
Results
PTA versus bypass surgery:  
subgroup analysis (II)
Late outcome after isolated  
infrapopliteal revascularization. 
Study II included 374 patients (36.6%) who 
underwent isolated infrapopliteal revascular-
ization. PTA was performed on 198 patients 
and popliteodistal bypass surgery on 176 pa-
tients. In the overall series of this subgroup, 
PTA was associated with significantly bet-
ter leg salvage at 5 years (75.5% vs. 68.0%, 
p=0.04), but with significantly lower free-
dom from surgical re-intervention (86.3% vs. 
95.9%, p=0.001). At 5 years, PTA and bypass 
surgery yielded similar results in terms of sur-
vival (47.2% vs. 39.5%, p=0.27), AFS (33.7% 
vs. 32.7%, p=0.58) and freedom from any re-
intervention (78.8% vs. 85.2%, p=0.17).
The propensity score was calculated also 
for this subgroup of patients. Its area un-53
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Study I 5 years p-value Study II 5 years p-value
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Kaplan-Meier’s estimates of late outcome in the overall series.  
































































































































































































































































































































































































































































     
     
     
     
     
     
     
     
     
     
     
     
     
     
     




















































































































































































































































































     




















































































































The effectiveness of infrainguinal 
percutaneous transluminal angioplasty in 





































































































































der the ROC curve was 0.76 (95% CI 0.71–
0.81, p<0.001).
When adjusted for the propensity score, 
PTA was associated with better leg salvage at 
5 years (p=0.04), but with a lower freedom 
from surgical re-intervention (p=0.002). The 
difference between the PTA and bypass sur-
gery groups was not statistically significant in 
terms of survival (p=0.27), AFS (p=0.78) or 
freedom from any re-intervention (p=0.17).
One-to-one propensity score matching 
provided 89 pairs of patients who under-
went an isolated infrapopliteal revascular-
ization. Here, PTA tended to achieve bet-
ter leg salvage at 5 years (79.2% vs. 68.6%, 
p=0.12), but was associated with a lower free-
Study I Study II
241 pairs 
of patients 5 years p-value
208 pairs 
of patients 5 years p-value

























































Kaplan-Meier’s estimates of late outcome in the propensity-score-matched pairs.  
The number of patients entering intervals is reported in parentheses.
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dom from surgical re-intervention (85.9% 
vs. 93.1%, p=0.03) when compared to by-
pass surgery. The difference between PTA 
and bypass surgery groups was not statisti-
cally significant at 5 years in terms of surviv-
al (38.9% vs. 35.6%, p=0.89), AFS (30.5% 
vs. 29.5%, p=0.82) or freedom from any re-
intervention (82.1% vs. 84.0%, p=0.60).
Study III
The baseline clinical characteristics and 
procedural data of the study population are 
given in Table 12. A re-intervention was re-
quired for 58 (24%) legs. The most distal 
level treated was the femoropopliteal seg-
ment in 132 (55%) legs and interventions ex-
tending to infrapopliteal arteries were per-
formed on 108 (45%) legs.
The mean follow-up was 17 months. AFS 
was 91%, 71%, 61% and 49% at 30 days, 6 
months, 1 year and during the whole follow-
up period, respectively. Leg salvage was 96%, 
88%, 83% and 80% at 30 days, 6 months, 1 
year and during the whole follow-up period, 
respectively. Fourteen percent of the patients 
had died, lost their leg or undergone second-
ary bypass surgery at 30 days post-procedur-
ally and this figure was 37%, 48% and 58% 
at 6 months, 1 year and during the whole fol-
low-up period. 
Multivariate analysis of  
the primary outcome measures
In the multivariate analysis, the independent 
risk factors associated with death within 6 
months after the primary procedure were age 
(p=0.003, hazard ratio (HR)=1.1; 95% CI 1.0–
1.1), cardiac morbidity (p=0.021, HR=2.9; 95% 
CI 1.2–7.2), inability to ambulate upon hospi-
tal arrival (p=0.006, HR=3.0; 95% CI 1.4–6.5), 
and renal insufficiency (p=0.008, HR=2.5; 
95% CI 1.3–5.0). Surprisingly, patients with a 
normal or mediasclerotic pre-procedural ABI 
(ABI ≥0.9) had the highest 6-month mortal-
ity when compared to those with a lowered 
(≤0.89) pre-procedural ABI. For instance, the 
patients whose pre-procedural ABI was in the 
range of 0.6–0.89 had a significantly lower 
mortality rate at 6 months when compared to 
those with a normal (0.9–1.29) pre-procedural 
ABI (p=0.003, HR=0.2; 95% CI 0.1–0.6).
The significant predictors of amputation 
within 6 months after the primary interven-
tion were an urgent procedure (p=0.022, 
HR=2.8; 95% CI 1.2–6.5), the inability to am-
bulate upon hospital arrival (p=0.001, HR=4.3; 
95% CI 1.9–10.2) and gangrene as the indi-
cation for the procedure (p=0.023, HR=2.9; 
95% CI 1.2–7.3).
Compared to an ulcer, gangrene was signif-
icantly more strongly associated with amputa-
tion at 6 months (p=0.023, HR=3.0; 95% CI 
95% 1.2–7.8).
Table 16
Independent risk factors associated with overall mortality.
HR=hazard ratio, CI=confidence interval
HR (95% CI) p-value
Age/year 1.03 (1.01–1.1) 0.005
Cardiac morbidity 2.3 (1.3–4.1) 0.003
Inability to ambulate 2.3 (1.4–4.0) 0.002
Renal insufficiency 2.6 (1.6–4.4) 0.000
Dyslipidaemia 0.5 (0.3–0.8) 0.006
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The only independent risk factor associat-
ed with the need for secondary bypass sur-
gery within 6 months after the primary pro-
cedure was the inability to ambulate upon 
hospital arrival (p=0.045, HR=2.7; 95% CI 
1.02–7.0).
Multivariate analysis of  
the secondary outcome measures
In the multivariate analysis, the indepen-
dent risk factors associated with overall 
mortality were age, cardiac morbidity, the 
inability to ambulate upon hospital arriv-
al and renal insufficiency. Dyslipidaemia 
had a protecting effect in regard to overall 
mortality. Table 16 summarizes the respec-
tive hazard ratios, confidence intervals and 
p-values.
The significant predictors of amputation 
during the whole follow-up period were an 
urgent procedure, the inability to ambulate 
upon hospital arrival, gangrene as the indi-
cation for the procedure and a mediascle-
rotic pre-procedural ABI (≥1.3). Table 17 sum-
marizes the respective hazard ratios, confi-
dence intervals and p-values.
Compared to an ulcer, gangrene was sig-
nificantly more strongly associated with am-
putation during the whole follow-up period 
(p=0.014, HR=2.6; 95% CI 1.2–5.4).
The independent risk factors associat-
ed with the overall need for secondary by-
pass surgery were an urgent procedure 
(p=0.024, HR=2.7; 95% CI 1.1–6.6) and a 
vessel-related complication during the pri-
mary procedure (p=0.044, HR=3.1; 95% CI 
1.03–9.6). 
The significant predictors of any re-inter-
vention were gangrene (p=0.000, HR=2.6; 
95% CI 1.6–4.5), a vessel-related com-
plication during the primary procedure 
(p=0.004, HR=3.7; 95% CI 1.5–9.0) and for-
mer arterial thrombosis (p=0.000, HR=3.5; 
95% CI 1.9–6.5). 
The independent risk factors for the 
need for endovascular re-interventions 
were a mediasclerotic pre-procedural ABI 
(≥1.3; p=0.003, HR=4.0; 95% CI 1.6–10.3) 
and gangrene (p=0.032, HR=2.4; 95% CI 
1.1–5.2). 
Study IV
In the first round of evaluation, the κfree be-
tween all observers was 0.32 with a range of 
0.11–0.54 between two observers, a mean of 
0.27 and a median of 0.15.
After the intervention, the inter-observer 
agreement increased, but still remained be-
low the adequate inter-observer agreement: 
κfree between all observers was 0.49 with a 
Table 17
Independent risk factors associated  
with the overall amputation rate
HR=hazard ratio, CI=confidence interval
HR (95% CI) p-value
Urgent procedure 2.7 (1.3–5.6) 0.007 
Inability to ambulate 3.8 (1.9–7.7) 0.000
Gangrene 2.5 (1.2–5.2) 0.012
ABI ≥1.3 2.2 (1.1–4.5) 0.023
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range of 0.2–0.56 between two observers, a 
mean of 0.37 and a median of 0.36.
Agreement between two observers varied 
from 38% to 69% in the first round and be-
tween 51% and 73% in the second round. 
Agreement between all seven investigators 
was reached in only 7% and 19% of the cas-
es in the first and second round, respective-
ly. Even among the three most experienced 
observers, the κfree was only 0.49 at its high-
est in the second round.
Because there are several lesion types that 
do not fit any of the TASC II classes, an at-
tempt was made to increase inter-observer 
agreement by combining classes. Only when 
classes A and B were combined, with classes 
C and D remaining separate, was there ad-
equate inter-observer agreement as the κfree 
reached a value of 0.71 in the second round. 
Study V
The clinical symptoms were described in 
346 (99%) of the referrals, ABI values were 
reported in 166 (47%) and toe pressures in 
193 (55%) of the referrals. Pulse palpation 
status was included in 103 (29%) referrals. 
All key pieces of information were included 
in 69 (20%) referrals, whereas in 112 (32%) 
referrals the informational content was un-
satisfying, as 107 (31%) of these included on-
ly one key piece of information and five (1%) 
included no relevant information about the 
patient. When procedures were performed 
on the basis of the referrals including all 
the key pieces of information, the compli-
cation and/or technical failure rate was 7 
(10%), while this figure was 22 (20%) for 
those with unsatisfying informational con-
tent (p=0.009).
A total of 151 (43%) referrals led to DSA 
only, 173 (49%) referrals to PTA and 27 (8%) 
to stenting.
Problems in crossing the arterial lesions 
with a guidewire and technical difficulties 
due to, for example, kinking of the catheters 
led to 30 (9%) procedures being complete 
immediate technical failures. In 16 (5%) 
cases, PTA was successful in only a part of 
the arterial lesions, as attempts to treat le-
sions at multiple levels were not all success-
ful. A complication (vessel perforation, dis-
tal embolization or thrombosis) occurred in 
13 (4%) procedures.
A vascular surgeon was consulted on 14 
(4%) of the occasions, and a vascular sur-
geon was a co-operator on 24 (7%) occa-
sions.
In 270 (77%) of the cases, the imaging 
or the procedure performed at the Depart-
ment of Radiology corresponded to the re-
quest made in the referral letter, or a vascu-
lar surgeon was a co-operator or consulted 
before changing the strategy. 
Altogether, the radiologist independently 
performed endovascular interventions that 
were not requested on 74 (21%) occasions.
In 7 instances where a specific interven-
tion was requested based on other vascular 
imaging, the intervention requested in the 
referral was performed successfully, but 
additional lesions were also treated at the 
independent decision of the radiologist. Of 
these cases, problems were encountered in 
86%, as 1 led to a complication and 5 were 
immediate technical failures.
On 70 (20%) occasions, an endovascular 
procedure was performed even if only DSA 
was requested. In only 2 of these, a vascular 
surgeon was consulted before extending the 
DSA to an intervention, and in 1 of them a 
vascular surgeon was a co-operator.
When the interventional radiologist in-
dependently made the decision to perform 
an intervention not requested in the refer-
ral, the result was a complication and/or a 
technical failure significantly more often 
(p=0.007) than when the referral request 
was followed or a vascular surgeon was con-
sulted beforehand.
In 7 (2%) instances, less was done than 
what was requested due to, for example, pa-
tient-related problems (e.g., restlessness). ❦
Outcomes of infrainguinal  
revascularization for CLI 
At present, the BASIL trial remains the on-
ly one large multicentre randomized con-
trolled trial comparing bypass surgery and 
endovascular interventions for SLI (Adam et 
al. 2005). The inclusion criterion was based 
on uncertainty – that is, the vascular sur-
geon and the interventional radiologist be-
lieved it was appropriate to offer the patient 
either revascularization method. As a result, 
only 10% of all SLI patients presenting at the 
centres involved in the study were actually 
enrolled, demonstrating low external valid-
ity (Conte 2010a). This problem has also been 
encountered in other randomized trials; the 
higher the requirement for internal validity, 
the fewer patients are eligible for the study 
(Cull et al. 2010, Lepäntalo et al. 2009). On the 
other hand, the strength of a registry-based 
study is the large coverage of the patients in 
daily practice and the avoidance of selection 
bias. However, in non-randomised observa-
tional studies, investigators have no control 
over treatment assignment and the patient groups tend to differ in 
terms of risk factors and arterial lesions treated. This problem can 
be partially compensated for by using balancing scores such as the 
propensity score. It is a multivariable statistical method that iden-
tifies patients with similar chances of receiving one or the other 
treatment, thus permitting non-randomized comparisons of treat-
ment outcomes (Blackstone, 2002). In Studies I and II, the propensity 
score was used for regression adjustment and for one-to-one match-
ing. In both studies, the one-to-one propensity score matching re-
sulted in treatment groups with very similar measured covariates. 
The area under the ROC curve for the obtained propensity score 
was satisfactory, especially considering the fact that the differences 
between the study groups – i.e., patients undergoing two different 
treatment methods – are likely to be less marked than what is often 
Discussion
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observed among patients with or without an 
outcome endpoint.
AFS is considered the most important out-
come endpoint in the treatment of CLI (Nor-
gren et al. 2010). In Study I, arterial lesions 
in the femoropopliteal segment were treat-
ed, and there was no significant difference 
in AFS between the two treatment groups 
after risk adjustment. However, bypass sur-
gery was associated with significantly better 
leg salvage in the long term when compared 
to PTA. This might imply possible benefits 
of treating CLI patients with probable lon-
gevity with bypass surgery as the first-line 
strategy.
On the other hand, in Study II, proce-
dures extending to infrapopliteal arteries 
were performed with or without simultane-
ous treatment of femoropopliteal lesions, 
and there was no significant difference be-
tween the two revascularization methods 
in terms of AFS or limb salvage. In fact, in 
the subgroup analysis on patients who un-
derwent isolated infrapopliteal revascular-
ization, leg salvage was actually significant-
ly better in the PTA group. Nevertheless, in 
this subgroup analysis, the freedom from 
surgical re-interventions was significantly 
lower in the PTA group, implying that active 
redo-surgery policy is mandatory to achieve 
appropriate outcome.
In the BASIL trial, the need for re-inter-
ventions was higher in the PTA-first group 
when compared to the surgery-first group. 
Also in Studies I and II, the freedom from 
surgical re-interventions was lower in the 
PTA group across the board. This is in con-
cordance with previous reports of inferior 
patency of the endovascular approach com-
pared to surgery (Romiti et al. 2008). It is al-
so due to our general practice: if CLI symp-
toms are not relieved and the endovascular-
ly treated segment has occluded, the thresh-
old for surgical re-intervention is relative-
ly low. Redo-PTA is opted for only in cas-
es with mild to moderate recurrent symp-
toms.
The freedom any re-intervention was sim-
ilar between the two revascularization meth-
ods in Studies I and II. Most probably our 
active surveillance policy on venous grafts 
and the mostly endovascular treatment of 
graft stenoses were the reasons for the equal 
rates of any re-interventions between the 
treatment groups.
Nonambulatory status upon hospital arriv-
al was independently associated with all the 
primary outcome measures as well as with 
overall mortality and amputation in Study 
III. Here, chronically bedridden patients 
were not revascularized. The ambulatory 
status was recorded upon hospital arrival 
and hence the mobility of the patient could 
have been better before the onset of CLI. In 
the elderly, the general condition often de-
teriorates quickly when patients lose their 
ability to walk. The nonambulatory patients 
also often have more comorbities than those 
ambulating independently, and the loss of 
mobility may also be a sign of the patient’s 
worsening overall condition and not nec-
essarily a reflection of local ischaemic leg 
symptoms. Moreover, as the nonambulatory 
status was an independent predictor of sec-
ondary bypass surgery at 6 months, it might 
be that secondary surgery brought upon ad-
verse events or increased physical burden 
thus further contributes to the poor progno-
sis observed here. The results of the study 
further support those of previous investiga-
tions in which the CLI patient’s impaired 
preoperative mobility has been associated 
with poor outcome even in the presence of a 
patent graft (Flu et al. 2010, Simons et al. 2010, 
Taylor et al. 2009).  
In Study III, gangrene was an indepen-
dent risk factor for amputation and was sig-
nificantly more strongly associated with it 
compared to ulcer. As a matter of fact, ulcer 
did not differ from rest pain as a risk factor 
for amputation in the present series. Simi-62
lar results have been demonstrated in ear-
lier studies (Biancari et al. 2007, Taylor et al. 
2009). Gangrene is always a consequence of 
markedly reduced circulation, while an ul-
cer may also have other aetiologic compo-
nents, such as neuropathy. Consequently, 
the healing of an ulcer may be more likely 
when offloading is achieved together with 
revascularization than when gangrene is 
present. Nevertheless, the most commonly 
used clinical classifications for CLI include 
ischaemic ulcer and focal gangrene in the 
same class, and they are often discussed as 
one entity, namely tissue loss (Fontaine et al. 
1955, Rutherford et al. 1997).
If a patient presented with the two inde-
pendent predictors discussed above, non-
ambulatory status and gangrene, the out-
come was extremely poor – after 6 months, 
67% had died or lost their limb and after 
one year this figure was 83%.
Significance of the TASC II classification 
for femoropopliteal arterial lesions 
The TASC II document provides the cur-
rently most widespread and applied classi-
fication of the morphological changes in the 
lower limb vasculature in PAD (Norgren et 
al. 2007). The four different grades in this 
classification are based on several elements, 
such as the type of lesion (stenosis or occlu-
sion) as well as the number, length and lo-
calisation of the lesion. This illustrates that, 
occasionally, disagreement arises, when the 
classification is applied in clinical practise. 
On the other hand, the classification of ar-
terial lesions can be rather difficult, as most 
cases of PAD, especially CLI, requiring in-
tervention are characterized by more than 
one lesion at more than one level. 
The poor inter-rater agreement in the first 
round of the study came perhaps as no sur-
prise, as the observers classified the lesions 
on the basis of self-education using the 
printed TASC II document. Nonetheless, 
even after two educational interventions, the 
inter-observer agreement remained poor. 
Since the publication of the present study, 
the poor reproducibility of TASC II classifi-
cation has also been demonstrated in other 
studies (Bradbury et al. 2010c).
There are some shortcomings related to 
the TASC II classification of femoropoplite-
al lesions. Firstly, no definition for stenosis 
or total occlusion is provided. Because the 
lesions may be complex and consist of seg-
ments with milder and more severe steno-
ses and occlusions, variations occur in the 
interpretation of lesion length and num-
ber. Furthermore, the delineation of heav-
ily calcified lesions by viewing angiograms 
is a potential source of inter-observer vari-
ability, and the degree of calcification cannot 
even be reliably estimated on MRA, which 
is currently the preferred preoperative imag-
ing modality in many centres (Lakshminaray-
an et al. 2009, Norgren et al. 2007). Moreover, 
some of the written definitions of the lesions 
do not match the illustrations, creating con-
fusion. Lastly, some lesion patterns do not 
fit any of the TASC II classes, which contrib-
utes to the decline in inter-observer agree-
ment. A more complex classification would 
be required to adequately describe the fem-
oropopliteal arterial lesions, but then again, 
this might lead to decreased applicability of 
the classification in daily practice. 
Communication and decision-making 
during angiography 
The communication between the vascular 
surgeon and interventional radiologist is 
frequently based only on the referral text. 
Therefore, it is mandatory that it contain ad-
equate data to allow the optimal treatment 
of CLI patients. This study revealed that the 
information value of the referrals made by 
vascular surgeons was rather poor, as the 
majority of them were incomplete. The 
proportion of complications and/or tech-
nical failures of the endovascular interven-
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ral was twice as high as of those executed on 
the basis of a good referral. Although this 
difference did not reach statistical signifi-
cance, it points to the importance of the re-
ferral’s good informational quality. There-
fore, more effort is required from the vas-
cular surgeons to improve the information-
al content of their referrals to facilitate the 
evaluation of the proper approach and plan-
ning of DSA with or without intervention.  
In the majority of the cases, the execution 
of imaging or interventions at the Depart-
ment of Radiology corresponded well with 
the referral. On the other hand, the radiolo-
gists made treatment decisions of their own 
in 21% of the instances. This seemed per-
haps unnecessarily risky, as these interven-
tions resulted in significantly more compli-
cations and/or technical failures than those 
executed on request. After all, in the BA-
SIL trial, patients who underwent surgi-
cal bypass after an initial failed angioplasty 
did fare significantly worse than those who 
were initially treated with bypass surgery 
(Bradbury et al. 2010d). Moreover, the over-
all clinical responsibility for a CLI patient’s 
treatment strategy is also legally designated 
for the vascular surgeon.  
A mixed team approach could help to de-
crease problems in communication. Efforts 
to improve the communication and multidis-
ciplinary teamwork have been made, as each 
day one of the vascular surgeons is assigned 
to be the vascular consult and since 2007 two 
vascular surgeons have regularly performed 
endovascular procedures at the department 
of radiology. At our clinic, the radiologists do 
not participate in the clinical evaluation of 
CLI patients. This could, however, make the 
teamwork stronger and justify therapeutic 
decision-making also for the radiologist.  
Study limitations   
A concern for data validity and complete-
ness is typically associated with registry-
based studies, which is the nature of Studies 
I–III. Efforts were made to minimize these 
limitations. Our vascular registry includes 
all patients that have undergone any type 
of revascularization, endovascular or sur-
gical. The completeness of the registry da-
ta has been checked against hospital regis-
tries, and missing data have been complet-
ed afterwards. The key outcome endpoints 
were double-checked against official nation-
al registries. Yet, no registry is immune for 
omissions and differences in the interpre-
tation of the data (Kantonen et al. 1997, Taha 
et al. 2008).
In Studies I and II, the one-to-one pro-
pensity score matching resulted in treat-
ment groups with very similar measured co-
variates, yet we were unable to include the 
characteristics of treated lesions as an un-
ambiguous covariate. The anatomy of the 
treated lesions was registered according to 
the TASC II classification. However, this was 
not included in the analysis due to the poor 
inter-rater agreement in grading the femo-
ropopliteal arterial lesions that was observed 
in a previous study of ours (Study IV). As 
the patients who undergo bypass surgery 
tend to have a more widespread configura-
tion of arterial occlusive disease, the lesions 
treated by PTA were probably shorter and 
less severe than those treated surgically.
The difference in the routine surveillance 
protocol of the two revascularization strate-
gies is additionally a possible limitation of 
Studies I and II. Even though all patients 
were followed until their symptoms subsid-
ed and/or wounds healed, routine clinical 
examination and ABI measurements were 
performed up to 4 weeks post-procedurally 
for the PTA group, whereas they were per-
formed up to 12 months alongside DD for 
the bypass surgery group. It is therefore 
probable that the first signs of re-stenosis 
and limb ischaemia were detected earlier 
in the bypass surgery group. Even though 
there is no consensus to date on how en-
dovascularly treated patients should best be 64
followed, our surveillance protocols have re-
cently been changed so that they are now 
identical for both, the surgical and endovas-
cular, revascularization strategies.
The dual antiplatelet therapy with clopi-
dogrel and aspirin for one month after an 
endovascular procedure has been in routine 
use at our clinic since 2001. However, there 
is variation in the postinterventional anti-
thrombotic medication policy from centre 
to centre. There is no direct evidence to sup-
port the use of dual antiplatelet therapy af-
ter infrainguinal PTA, and this regimen has 
principally been adopted on the basis of da-
ta from the coronary field (Chenet al. 2005, 
Mehta et al, 2001, Yusuf et al. 2001). Moreover, 
the proportion of stents currently used in-
frainguinally in the treatment of CLI is in-
creasing and is significantly higher in many 
centres compared ours (Conrad et al. 2011). 
Therefore, the results of Studies I–III might 
not be directly transferable to everyday clin-
ical practise in many centres. In our cen-
tre, a selective stenting policy has been ad-
opted, since the current data does not sup-
port routine stenting over selective stenting 
(Kasapis et al. 2009, Twine et al. 2009). For in-
stance, in the meta-analysis by Kasapis et 
al. including 10 RCTs with a total of 1,343 
patients and 1,442 limbs, no definitive evi-
dence favouring one stenting strategy over 
the other was found. Given the absence of 
data to the contrary and the lower equip-
ment cost, the authors conclude that selec-
tive stenting should remain the preferred 
endovascular therapy.
Furthermore, possible limitations of 
Study III are the relatively small numbers 
of patients, especially in the subgroups, and 
a relatively short follow-up. Additionally, the 
retrospective nature of the study and the ab-
sence of a control group may cause bias. 
In Study IV, the length of the lesions was 
not accurately measured with an electronic 
measure during the classification process, 
which can be considered a weakness of the 
study and a possible explanation for poor 
inter-observer agreement. Additionally, in-
creasing the time spent grading each case 
might have improved the agreement. How-
ever, the outcome was no better among a 
subgroup of very experienced investigators 
who were highly familiar with this particu-
lar classification system.
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1. When technically feasible, infrainguinal PTA seems to be a  
valid alternative for bypass surgery in the treatment of CLI when 
redo-surgery is actively utilized. However, in the treatment of 
femoropopliteal lesions, PTA might be associated with poorer 
leg salvage in the long term when compared to bypass surgery, 
although treatment method did not affect AFS. Bypass surgery 
could likely be considered as a better alternative in patients with 
probable longevity.
2. Strong predictors of poor outcome after PTA for patients  
with CLI are cardiac morbidity, nonambulatory status upon  
hospital arrival and gangrene as a manifestation of CLI.  
Gangrene is significantly more strongly associated with the  
risk of limb loss than ulcer.  
3. The TASC II classification of femoropopliteal arterial lesions  
allows individual interpretations, and its reproducibility seems 
to be rather poor. Its common use as a basis for therapeutic  
decision-making and for reporting outcomes in scientific  
literature can therefore be questioned.
4. The communication between vascular surgeons and  
interventional radiologists seems to be insufficient to ensure  
optimal treatment for CLI patients. A mixed-team approach 
could help decrease these problems. ❦
Conclusions
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